



May 2017

Drug Information Update

TABLE OF CONTENTS

NEWLY AVAILABLE GENERICS	2
NEW DRUG ENTITIES/COMBINATIONS/STRENGTHS	3
NEW INDICATIONS (EXISTING DRUGS)	7
FDA NEWS/BULLETINS/ADVISORIES/SAFETY ALERTS	9
STUDIES and RECENT TOPICS.....	12
RECALLS.....	15
CURRENT DRUG SHORTAGES.....	22

NEWLY AVAILABLE GENERICS

GENERIC DRUG NAME	STRENGTH & DOSAGE FORM	GENERIC MANUFACTURER	BRAND NAME
EZETIMIBE/SIMVASTATIN	10 mg-10 mg	IMPAX GENERICS	VYTORIN
EZETIMIBE/SIMVASTATIN	10 mg-20 mg	IMPAX GENERICS	VYTORIN
EZETIMIBE/SIMVASTATIN	10 mg-80 mg	IMPAX GENERICS	VYTORIN
EZETIMIBE/SIMVASTATIN	10 mg-40 mg	IMPAX GENERICS	VYTORIN
FLUTICASONE/SALMETEROL	55 mcg-14 mcg/actuation	TEVA USA	AIRDUO RESPICLICK
FLUTICASONE/SALMETEROL	113 mcg-14 mcg/actuation	TEVA USA	AIRDUO RESPICLICK
FLUTICASONE/SALMETEROL	232 mcg-14 mcg/actuation	TEVA USA	AIRDUO RESPICLICK
ACETAMINOPHEN/CAFF/DIHYDROCOD	325 mg-30 mg-16 mg	LARKEN LABS	ACETAMIN-CAFF-DIHYDROCODEINE

NEW DRUG ENTITIES/COMBINATIONS/STRENGTHS

DESCRIPTION	BRAND NAME	GENERIC NAME	STRENGTH	NOTES
BETA-ADRENERGIC AND GLUCOCORTICOID COMBO, INHALED	AIRDUO RESPICLICK	FLUTICASONE/SALMETEROL	55 mcg-14 mcg/actuation	NEW STRENGTH AND DOSAGE FORM
BETA-ADRENERGIC AND GLUCOCORTICOID COMBO, INHALED	AIRDUO RESPICLICK	FLUTICASONE/SALMETEROL	113 mcg-14 mcg/actuation	NEW STRENGTH AND DOSAGE FORM
BETA-ADRENERGIC AND GLUCOCORTICOID COMBO, INHALED	AIRDUO RESPICLICK	FLUTICASONE/SALMETEROL	55 mcg-14 mcg/actuation	NEW STRENGTH AND DOSAGE FORM
NARCOTIC ANALGESIC, NON-SALICYLATE, XANTHINE COMB	ACETAMIN-CAFF-DIHYDROCODEINE	ACETAMINOPHEN/CAFF/DIHYDROCOD	325 mg-30 mg-16 mg	NEW STRENGTH
NEUROTOXIC VIRUS VACCINES	STAMARIL	YELLOW FEVER VACCINE LIVE/PF	1,000 unit/0.5 mL	NEW STRENGTH NO PRICING AVAILABLE, CLAIMS WILL NOT PROCESS TILL PRICING IS PROVIDED
ANTIFIBROTIC THERAPY - PYRIDONE ANALOGS	ESBRIET	PIRFENIDONE	267 mg	NEW STRENGTH
ANTIFIBROTIC THERAPY - PYRIDONE ANALOGS	ESBRIET	PIRFENIDONE	801 mg	NEW STRENGTH
PEDIATRIC VITAMIN PREPARATIONS	MULTIVITAMIN WITH FLUORIDE	PED MULTIVIT NO.150 W-FLUORIDE	0.25 mg fluoride/mL ORAL SOLUTION	NEW STRENGTH

DESCRIPTION	BRAND NAME	GENERIC NAME	STRENGTH	NOTES
PEDIATRIC VITAMIN PREPARATIONS	MULTIVITAMIN WITH FLUORIDE	PED MULTIVIT NO.150 W-FLUORIDE	0.5 mg fluoride/mL ORAL SOLUTION	NEW STRENGTH
DRUGS TO TREAT MOVEMENT DISORDERS	INGREZZA	VALBENAZINE TOSYLATE	40 mg	NEW ENTITY
ANTINEOPLASTIC - ALKYLATING AGENTS	TEPADINA	THIOTEPA	100 mg IV INJECTION	NEW STRENGTH
ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS	ZEJULA	NIRAPARIB TOSYLATE	100 mg ORAL SOLUTION	NEW ENTITY
PEDIATRIC VITAMIN PREPARATIONS	QUFLORA FE	PED MULTIVIT 151/IRON/FLUORIDE	9.5 mg iron-0.25 mg fluoride/mL ORAL SOLUTION	NEW COMBINATION
BONE FORMATION STIMULATING AGTS - PTH REL PEPTIDES	TYMLOS	ABALOPARATIDE	80 mcg/dose (3,120 mcg/1.56 mL) SUBQ INJECTION	NEW ENTITY
TOPICAL LOCAL ANESTHETICS	LIDOPAC	LIDOCAINE	5% TOPICAL	NEW DOSAGE FORM
ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS	RYDAPT	MIDOSTAURIN	25 mg	NEW ENTITY
ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS	ALUNBRIG	BRIGATINIB	30 mg	NEW ENTITY
ANTI-PROGRAMMED CELL DEATH-LIGAND 1 (PD-L1) MAB	IMFINZI	DURVALUMAB	120 mg/2.4 mL (50 mg/mL) IV INJECTION	NEW ENTITY

DESCRIPTION	BRAND NAME	GENERIC NAME	STRENGTH	NOTES
ANTI-PROGRAMMED CELL DEATH-LIGAND 1 (PD-L1) MAB	IMFINZI	DURVALUMAB	500 mg/10 mL (50 mg/mL) IV INJECTION	NEW ENTITIY
NARCOTIC ANTAGONISTS	NARCAN	NALOXONE HCL	2 mg/actuation	NEW STRENGTH AND DOSAGE FORM
OPHTH. VEGF-A RECEPTOR ANTAG. RCMB MC ANTIBODY	BEVACIZUMAB	BEVACIZUMAB	1 mg/0.04 mL IV INJECTION	NEW STRENGTH NO PRICING AVAILABLE
OPHTH. VEGF-A RECEPTOR ANTAG. RCMB MC ANTIBODY	BEVACIZUMAB	BEVACIZUMAB	1.25 mg/0.05 mL IV INJECTION	NEW STRENGTH NO PRICING AVAILABLE
MYDRIATICS	CYCLOPENTOLAT E-LIDOC-PE-TROPIC	CYCLOPEN HCL/LIDO/PE/TROPICAMI	0.05 %-1.7 %-0.5 %-0.05 % OPTHALMIC DROPS	NEW COMBINATIO N
ANTINEOPLASTIC - ANTIANDROGENIC AGENTS	ZYTIGA	ABIRATERONE ACETATE	500 mg	NEW STRENGTH
ANTINEOPLASTIC EGF RECEPTOR BLOCKER MCLON ANTIBODY	HERCEPTIN	TRASTUZUMAB	150 mg IV	NEW STRENGTH
ANTINEOPLASTIC COMB - KINASE AND AROMATASE INHIBIT	KISQALI FEMARA CO-PACK	RIBOCICLIB SUCCINATE/LETROZOLE	200 mg/day (200 mg x 1)- 2.5 mg	NEW COMBINATIO N
ANTINEOPLASTIC COMB - KINASE AND AROMATASE INHIBIT	KISQALI FEMARA CO-PACK	RIBOCICLIB SUCCINATE/LETROZOLE	400 mg/day (200 mg x 2)- 2.5 mg	NEW COMBINATIO N
ANTINEOPLASTIC COMB - KINASE AND AROMATASE INHIBIT	KISQALI FEMARA CO-PACK	RIBOCICLIB SUCCINATE/LETROZOLE	600 mg/day (200 mg x 3)- 2.5 mg	NEW COMBINATIO N

DESCRIPTION	BRAND NAME	GENERIC NAME	STRENGTH	NOTES
ANTIVIRALS, GENERAL	GANCICLOVIR	GANCICLOVIR	500 mg/250 mL (2 mg/mL IV BAG	NEW STRENGTH AND DOSAGE FORM

NEW INDICATIONS (EXISTING DRUGS)

Tecentriq®

April 17, 2017

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval to TECENTRIQ® (atezolizumab) for the treatment of people with locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for cisplatin chemotherapy. TECENTRIQ was previously approved for people with locally advanced or mUC who have disease progression during or following any platinum-containing chemotherapy, or within 12 months of receiving chemotherapy before surgery (neoadjuvant) or after surgery (adjuvant). It is not known if TECENTRIQ is safe and effective in children. Bladder cancer is the most common type of urothelial carcinoma, and up to half of all people with the advanced form of the disease are unable to receive cisplatin chemotherapy as an initial treatment and therefore have a high unmet medical need. Urothelial carcinoma also includes cancers of the urethra, ureters and renal pelvis.

Source: Genentech

<https://www.gene.com/media/press-releases/14660/2017-04-17/>

Lucentis®

April 17, 2017

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Lucentis® (ranibizumab injection) 0.3 mg for the monthly treatment of all forms of diabetic retinopathy. The most common cause of vision loss in people with diabetes, diabetic retinopathy is the leading cause of blindness among adults aged 20 to 741 and affects nearly 7.7 million people in the U.S.2 With this approval, Lucentis becomes the first and only FDA-approved medicine to treat diabetic retinopathy in people who have been diagnosed either with or without diabetic macular edema (DME), a complication of diabetic retinopathy that causes swelling in the back of the eye. In February 2015, Lucentis received FDA approval for the treatment of diabetic retinopathy in people with DME based on data from the pivotal RIDE and RISE Phase III clinical trials.

Source: Genentech

<https://www.gene.com/media/press-releases/14661/2017-04-17/fda-approves-genentechs-lucentis-ranibiz>

Thymoglobulin®

April 24, 2017

BRIDGEWATER, N.J., April 24, 2017 /PRNewswire/ -- Sanofi today announced that the U.S. Food and Drug Administration (FDA) approved Thymoglobulin® [anti-thymocyte globulin (rabbit)], for use in conjunction with concomitant immunosuppression in the prophylaxis, or prevention, of acute rejection in patients receiving a kidney transplant.

Source: Sanofi

<http://www.news.sanofi.us/2017-04-24-Sanofi-Receives-FDA-Approval-of-Thymoglobulin-R-for-the-Prevention-of-Acute-Kidney-Transplant-Rejection>

Stivarga®

April 27, 2017

Whippany, N.J., April 27, 2017 – Bayer announced today that the U.S. Food and Drug Administration (FDA) approved Stivarga® (regorafenib) tablets for the second-line treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with Nexavar® (sorafenib).2 Stivarga is the first and only treatment to demonstrate significant improvement in overall survival in second-line HCC patients.2 In the RESORCE trial, Stivarga was shown to provide a statistically significant and clinically meaningful improvement in overall survival

(OS) versus placebo; the median OS was 10.6 [(n=379) (CI 9.1, 12.1)] vs 7.8 [(n=194) (CI 6.3, 8.8)] months, respectively (HR 0.63, 95% CI 0.50-0.79; p<0.0001).² This translates to a 37% reduction in the risk of death. The number of deaths in each arm included 233 of 379 (62%) with Stivarga and 140 of 194 (72%) with placebo.² Today's FDA approval expands Bayer's leadership in liver cancer with a treatment plan in HCC involving use of Stivarga directly after progression on Nexavar.

Source: Bayer

<https://www.multivu.com/players/English/8002351-bayer-stivarga-fda-approval/?c=y>

FDA NEWS/BULLETINS/ADVISORIES/SAFETY ALERTS

Tramadol Medicines: Drug Safety Communication - Restricting Use in Children, Recommending Against Use in Breastfeeding Women

[Posted 4/20/2017]

ISSUE: FDA is restricting the use of codeine and tramadol medicines in children. These medicines carry serious risks, including slowed or difficult breathing and death, which appear to be a greater risk in children younger than 12 years, and should not be used in these children. These medicines should also be limited in some older children. Single-ingredient codeine and all tramadol-containing products are FDA-approved only for use in adults. FDA is also recommending against the use of codeine and tramadol medicines in breastfeeding mothers due to possible harm to their infants.

As a result, FDA is requiring several changes to the labels of all prescription medicines containing these drugs. These new actions further limit the use of these medicines beyond the 2013 FDA restriction of codeine use in children younger than 18 years to treat pain after surgery to remove the tonsils and/or adenoids. FDA is now adding:

- FDA's strongest warning, called a Contraindication, to the drug labels of codeine and tramadol alerting that codeine should not be used to treat pain or cough and tramadol should not be used to treat pain in children younger than 12 years.
- A new Contraindication to the tramadol label warning against its use in children younger than 18 years to treat pain after surgery to remove the tonsils and/or adenoids.
- A new Warning to the drug labels of codeine and tramadol to recommend against their use in adolescents between 12 and 18 years who are obese or have conditions such as obstructive sleep apnea or severe lung disease, which may increase the risk of serious breathing problems.
- A strengthened Warning to mothers that breastfeeding is not recommended when taking codeine or tramadol medicines due to the risk of serious adverse reactions in breastfed infants. These can include excess sleepiness, difficulty breastfeeding, or serious breathing problems that could result in death.

See the FDA Drug Safety Communication for a data summary, a list of approved drugs containing codeine and tramadol, and additional information.

BACKGROUND: Codeine is approved to treat pain and cough, and tramadol is approved to treat pain.

RECOMMENDATION: Health care professionals should be aware that tramadol and single ingredient codeine medicines are FDA-approved only for use in adults. Consider recommending over-the-counter (OTC) or other FDA-approved prescription medicines for cough and pain management in children younger than 12 years and in adolescents younger than 18 years, especially those with certain genetic factors, obesity, or obstructive sleep apnea and other breathing problems. Cough is often secondary to infection, not serious, and usually will get better on its own so treatment may not be necessary.

Caregivers and patients should always read the label on prescription bottles to find out if a medicine contains codeine or tramadol. You can also ask your child's health care provider or a pharmacist. Watch closely for signs of breathing problems in a child of any age who is taking these medicines or in infants exposed to codeine or tramadol through breastmilk. These signs include slow or shallow breathing, difficulty or noisy breathing, confusion, more than usual sleepiness, trouble breastfeeding, or limpness. If you notice any of these signs, stop giving the medicine and seek medical attention immediately by going to an emergency room or calling 911.

<https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm554029.htm>

Phenobarbital 15 mg Tablets, USP by C.O. Truxton: Recall - Labeling Error on Declared Strength
[Posted 4/21/2017]

ISSUE: C.O. Truxton, Inc. is voluntarily recalling lot 70952A of Phenobarbital Tablets, USP, 15 mg, to the consumer/user level. The manufacturer received a confirmed customer complaint that a bottle labeled as phenobarbital 15 mg was found to contain phenobarbital 30 mg tablets.

This mislabeled product could expose the consumer or their pet(s) to potential overdosing that can cause severe intoxication which may lead to cardiogenic shock, renal failure, coma or death.

BACKGROUND: The product is indicated for use as a sedative or anticonvulsant and is packaged in 1000 count bottles, NDC 0463-6160-10, UPC 7 0463616010 6, lot number 70952A, expiration date 11/17. The 15 mg Tablet is debossed with "West-ward 445" on one side and blank on the reverse side; the 30 mg Tablet is debossed with "West-ward 450" on one side and scored on the reverse side. The product was distributed Nationwide in the USA to Physician & Veterinarian Treatment Centers.

RECOMMENDATION: C.O. Truxton, Inc. is notifying all customers on record who purchased the affected product via US Mail which includes a recall letter, recall response form and is arranging for full credit returns, replacements, etc. of all recalled product. Consumers/distributors/retailers that have recalled product should stop using the product and return their product to their place of purchase.

Consumers with questions regarding this recall can contact C.O Truxton, Inc. by phone at (856) 933-2333, Monday to Friday between the hours of 9am and 5pm (EST). Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

<https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm554358.htm>

25% Dextrose Injection, USP (Infant) by Hospira: Recall - Particulate Matter
[Posted 4/24/2017]

ISSUE: Hospira is voluntarily recalling one lot of 25% Dextrose Injection, USP, (Infant) prefilled syringe to the hospital/user level due to the presence of particulate matter, identified as human hair, found within an internal sample syringe. The affected lot is NDC: 0409-1775-10, Lot 58382EV, Expiry Date 1OCT 2017

In the event that the particulate is administered to a patient, it could result in local swelling, irritation of blood vessels or tissue, blockage of blood vessels and/or systemic allergic response to the particulate. Administration of the particulate could also result in localized phlebitis, pulmonary emboli, pulmonary granulomas, immune system dysfunction, pulmonary dysfunction, and pulmonary infarction.

BACKGROUND: 25% Dextrose Injection, USP (Infant) is indicated for use via slow IV injection to treat symptomatic episodes of hypoglycemia (fasting blood glucose < 40 mg/100 ml) in neonates or older infants to restore depressed blood glucose values and control symptoms.

25% Dextrose Injection, USP (Infant) 2.5 grams (250 mg/mL), 10 mL Single-dose prefilled syringe, NDC: 0409-1775-10, Lot 58382EV, Expiry Date 1OCT 2017 is packaged in a carton containing 1 pre- filled syringe per carton, 5 x 10 syringes per case. The lot was distributed from February 2016 through October 2016 nationwide in the United States and Puerto Rico.

RECOMMENDATION: Anyone with an existing inventory of the recalled lot should stop use and distribution and quarantine the product immediately. Inform health care professionals in your organization of this recall. If you have further distributed the recalled product, please notify any accounts or additional locations which may have received the recalled product from you. Further, please instruct entities that may have received the recalled

product from you that if they redistributed the product, they should notify their accounts, locations or facilities of the recall to the hospital/user level. For additional assistance, call Stericycle at 1-888-570-1678 between the hours of 8 a.m. to 5 p.m. ET, Monday through Friday.

STUDIES and RECENT TOPICS

Apple has a secret team working on the holy grail for treating diabetes

April 12, 2017

Apple has hired a small team of biomedical engineers to work at a nondescript office in Palo Alto, California, miles from corporate headquarters.

They are part of a super-secret initiative, initially envisioned by the late Apple co-founder Steve Jobs, to develop sensors that can noninvasively and continuously monitor blood sugar levels to better treat diabetes, according to three people familiar with the matter.

<http://www.cnbc.com/2017/04/12/apple-working-on-glucose-sensors-diabetes-treatment.html>

A Cautionary Tale About Antibiotics

April 14, 2017

Antibiotics are prescribed to treat infections from head to toe—from bronchitis to urinary tract infections (UTIs). But doctors and patients are increasingly learning more about the alarming side effects of one particular class called fluoroquinolones, which include Cipro and Levaquin. Rare cases of severe tendon damage associated with the use of the drug, among other side effects, have been reported in recent years.

<http://time.com/4720982/antibiotics-fluoroquinolones-risk/>

New in Wearable Health Tech: A Wrist Sensor That Works Up a Sweat

April 18, 2017

Researchers who are trying to find a way to make wearable health technology real say they've taken a big step with a device that generates enough sweat to be useful.

They've built a prototype that generates a few drops of perspiration — enough to measure blood sugar and to monitor other bodily functions..

<http://www.nbcnews.com/health/health-news/new-wearable-health-tech-wrist-sensor-works-sweat-n747841>

FDA Approves Vagus Nerve Stimulator to Treat Cluster Headaches

April 18, 2017

The Food and Drug Administration approved a device on Tuesday meant to treat cluster headaches — a rare form of headache that affects mostly men.

The device is a vagus nerve stimulator and it's not entirely clear how it works. The idea is to disrupt signals that run along the vagus nerve, a giant nerve that runs from the brain all the way to the colon. It's involved in many bodily responses.

<http://www.nbcnews.com/health/health-news/fda-approves-vagus-nerve-stimulator-treat-cluster-headaches-n748036>

Differing Statin Guidelines Leave Many Clinicians Uncertain

April 18, 2017

If all clinicians followed U.S. Preventive Services Task Force (USPSTF) guidelines for prescription of a statin, nine million fewer adults would be taking such medication versus adherence to the American College of

Cardiology/American Heart Association recommendations, according to a study published in the April 18 issue of the Journal of the American Medical Association.

<http://www.physiciansbriefing.com/Article.asp?AID=721791>

Alphabet's Verily unit launches study to track health data

April 19, 2017

Verily, Alphabet Inc's life sciences business, said it was launching a four-year study with about 10,000 participants to understand how people transition from being healthy to becoming sick, and to identify additional risk factors for diseases.

Verily is partnering with Duke University and Stanford Medicine in the United States to enroll participants from varying backgrounds at sites in California and North Carolina within the next few months.

<http://www.reuters.com/article/us-alphabet-verily-study-idUSKBN17L1NH>

Active ingredients in both hot peppers and cannabis calm the gut's immune system

April 24, 2017

You wouldn't think chili peppers and marijuana have much in common. But when eaten, both interact with the same receptor in our stomachs, according to a paper by UConn researchers published in the April 24 issue of the journal Proceedings of the National Academy of Sciences. The research could lead to new therapies for diabetes and colitis, and opens up intriguing questions about the relationship between the immune system, the gut and the brain.

<https://medicalxpress.com/news/2017-04-ingredients-hot-peppers-cannabis-calm.html>

Deaths From Infections May be Masking Opioid Deaths

April 24, 2017

The opioid abuse epidemic is already bad enough but doctors may be missing quite a few cases because of the way deaths are reported, disease detectives said Monday.

People who take the painkillers may be more susceptible to infections, and opioid drugs also suppress the immune system, making it harder to fight off those infections, researchers told a meeting at the Centers for Disease Control and Prevention.

<http://www.nbcnews.com/health/health-news/deaths-infections-may-be-masking-opioid-deaths-n750336>

Study: Medical-marijuana laws lower prescription drug usage

April 25, 2017

People with Medicaid coverage who live in states with medical marijuana laws are less likely to take medications commonly prescribed to treat conditions like nausea, pain, and depression, according to a new study.

The research, published last week in Health Affairs, looked at nine conditions and found reductions in prescriptions of medications used to treat depression (13%), nausea (17%), psychosis (12%), seizure disorders (12%), and pain (11%). There was no statistically significant difference for drugs used to treat anxiety, glaucoma, sleep disorders, and spasticity.

<http://www.mmm-online.com/commercial/study-medical-marijuana-laws-lower-prescription-drug-usage/article/652625/>

Researchers explore personalized pharmacotherapy to treat panic attacks

April 26, 2017

Although drug therapy is the accepted first-line treatment for panic disorders (PDs), 17% to 64% of patients do not respond adequately and continue to exhibit one of the most common symptoms of PD, the panic attack (PA). In a comprehensive new analysis published in *Personalized Medicine in Psychiatry*, researchers carefully reviewed scientific data to establish whether a personalized treatment approach could help physicians prescribe the drug that will work most effectively for a specific patient.

https://www.eurekalert.org/pub_releases/2017-04/ehs-rep042617.php

'Exciting' blood test spots cancer a year early

April 26, 2017

The UK team was able to scour the blood for signs of cancer while it was just a tiny cluster of cells invisible to X-ray or CT scans.

It should allow doctors to hit the tumour earlier and increase the chances of a cure.

<http://www.bbc.com/news/health-39658680>

Inexpensive Drug Prevents Deaths in New Mothers, Study Finds

April 26, 2017

An inexpensive generic drug that saves the lives of wounded soldiers and civilian car crash victims has now been shown to rescue women suffering hemorrhages in childbirth.

Postpartum hemorrhage, in which women bleed uncontrollably after childbirth, kills an estimated 100,000 women a year in poor and middle-income countries. The complication also forces doctors to perform emergency hysterectomies, especially when hospitals have too little blood on hand to provide transfusions.

https://www.nytimes.com/2017/04/26/health/inexpensive-drug-prevents-deaths-in-new-mothers-study-finds.html?_r=2

Zika Virus Persists in the Nervous System and Elsewhere

April 27, 2017

When the immune system has eliminated the last traces of Zika virus from the blood, low-level infection may continue at certain sites around the body. A study published in *Cell* today (April 27) reveals that the cerebrospinal fluid (CSF) is one such sanctuary, which, if also true for infected humans, may have implications for long-term neurological health.

<http://www.the-scientist.com/?articles.view/articleNo/49296/title/Zika-Virus-Persists-in-the-Nervous-System-and-Elsewhere/>

RECALLS

Product Type	Product Description	Class	Code Information	Reason for Recall	Recalling Firm
Drugs	EpiPen 2-Pak (Epinephrine) Auto-Injectors 0.3 mg, Rx only, Manufactured for Mylan Specialty L.P., Morgantown WV 26505 by Meridian Medical Technologies, Inc., Columbia, MD 21046, a Pfizer company; NDC 49502-500-02 ---- ALSO LABELED OUTSIDE THE US AS ---- EpiPen Auto-Injector 0.3 mg - Bright Stock labeled for multiple countries- manufactured for Mylan	Class I	US: lot 5GM631, exp. April 2017; lot 5GM640, exp. May 2017; lot 6GM072, exp. Sep 2017; lot 6GM082, exp. Sep 2017; lot 6GM088, exp. Oct 2017; lot 6GM087, exp. Oct 2017; lot 6GM198, exp. Oct 2017	Defective Delivery System; reports of the device failing to activate which could result in a patient not receiving medication	Meridian Medical Technologies a Pfizer Company 2555 Hermelin Dr Brentwood, MO 63144-2504
Drugs	EpiPen Jr. 2-Pak (Epinephrine) Auto-Injectors 0.15 mg, Rx only, Manufactured for Mylan Specialty L.P., Morgantown WV 26505 by Meridian Medical Technologies, Inc., Columbia, MD 21046, a Pfizer company; NDC 49502-500-02 ---- ALSO LABELED OUTSIDE THE US AS: EpiPen Auto-Injector Jr. 0.15 mg - Bright Stock labeled for multiple countries- manufactured for Mylan	Class I	US lot 5GN767, expiration April 2017; lot 5GN773, expiration April 2017; lot 6GN215, expiration Sep 2017; INTERNATIONAL lot 5GR765, expiration March 2017; lot 5GK771, expiration April 2017; lot 5ED824, expiration April 2017; and lot 6ED117, expiration ** *	Defective Delivery System; reports of the device failing to activate which could result in a patient not receiving medication	Meridian Medical Technologies a Pfizer Company 2555 Hermelin Dr Brentwood, MO 63144-2504
Drugs	hCG Body Shaper, Highly Purified Human Chorionic Gonadotrophin 5000 IU, Colloidal Silver B12, Stabilizers/Excipients, Not For Medical Use, Must Be Refrigerated, Distributed by HCG Body Shaper, St. Peters, MO	Class II	No code information printed on bottle	Marketed without an Approved NDA/ANDA; FDA analysis has found the product to be tainted with human chorionic gonadotropin, rendering it an unapproved drug	Gary Wood 1810 Oak Tree St Saint Peters, MO 63376-6617
Drugs	Nystatin and Triamcinolone Acetonide Cream, USP, 100,000 USP nystatin units and 1 mg triamcinolone acetonide, distributed in a) 15 grams (NDC 51672-1263-1), b) 30 grams (NDC 51672-1263-2) and c) 60 grams (NDC 51672-1263-3) tubes, Rx only, TARO label; Mfd. by: Taro Pharmaceuticals Inc. Brampton, Ontario, Canada L6T 1C1-- Dist. by: Taro Pharmaceuticals U.S.A. Inc., Hawthorne, NY 10532	Class II	a) 15 g: Lot B505118501, exp. date January 2018; b) 30 g: Lot B504918500, exp. date January 2018; c) 60 g: Lots: I416616979, exp. date August 2017, I416716979, exp. date August 2017 and D504519119, exp. date March 2018	Failed Content Uniformity Specifications; out-of-specification (OOS) results 18-month stability	Taro Pharmaceuticals U.S.A., Inc. 3 Skyline Dr Hawthorne, NY 10532-2174
Drugs	Methylprednisolone Acetate 40 mg/mL, Lidocaine HCl 10 mg/mL, 10 mL Multi-Dose Vial For Injection, Rx Only, Isomeric Pharmacy Solutions,	Class II	Lot #: 09007, Exp 04/04/17; 09016, Exp 04/16/17; 09020, Exp 04/18/17; 09025, Exp 04/23/17; 10026,	Lack of Assurance of Sterility: due to concerns with production processes which cannot assure sterility of	Isomeric Pharmacy Solution, LLC 2401 S Foothill Dr Ste D Salt Lake City, UT

Product Type	Product Description	Class	Code Information	Reason for Recall	Recalling Firm
	2401 Foothill Drive, SLC, UT 84109, Part # 1010, barcode 3 70285 10101 4.		10030, Exp 05/28/17; 110 07, Exp 05/30/17; 11008, Exp 05/31/17; 11020, Exp 06/07/17; 11028, Exp 06/12/17; 11043, Exp 06/26/17	products intended to be sterile.	84109-1479
Drugs	Methylprednisolone Acetate 80 mg/mL, Lidocaine HCl 10 mg/mL, 10 mL Multi-Dose Vial For Injection, Rx Only, Isomeric Pharmacy Solutions, 2401 Foothill Dr, SLC, UT 84109, Part # 1011, barcode 3 70285 10111 3.	Class II	Lot #: 09022, Exp 04/22/17; 10001, Exp 05/02/17; 11001, Exp 05/31/17; 110 10, Exp 06/03/17; 11037, Exp 06/19/17; 11041, Exp 06/25/17.	Lack of Assurance of Sterility: due to concerns with production processes which cannot assure sterility of products intended to be sterile.	Isomeric Pharmacy Solution, LLC2401 S Foothill Dr Ste D Salt Lake City, UT 84109-1479
Drugs	Triamcinolone Acetonide 40 mg/mL, Lidocaine HCl 10 mg/mL, 10 mL Multi-Dose Vial For Injection, Rx Only, Isomeric Pharmacy Solutions, 2401 Foothill Dr, SLC, UT 84109, Part # 1020, barcode 3 70285 10201 1.	Class II	Lot #: 09032, Exp 04/06/17; 10017, Exp 04/19/17; 10022, Exp 04/26/17; 100 31, Exp 05/04/17; 11021, Exp 05/17/17; 12007, Exp 06/16/17	Lack of Assurance of Sterility: due to concerns with production processes which cannot assure sterility of products intended to be sterile.	Isomeric Pharmacy Solution, LLC2401 S Foothill Dr Ste D Salt Lake City, UT 84109-1479
Drugs	Triamcinolone Diacetate 40 mg/mL, 10 mL Multi-Dose Vial For Injection, Rx Only, Isomeric Pharmacy Solutions, 2401 Foothill Drive, SLC, UT 84109, Part # 1021, barcode 3 70285 10211 0	Class II	Lot #: 10013, Exp 05/10/17; 10020, Exp 05/20/17; 10029, Exp 05/27/17; 110 02, Exp 05/30/17; 11013, Exp 06/04/17	Lack of Assurance of Sterility: due to concerns with production processes which cannot assure sterility of products intended to be sterile.	Isomeric Pharmacy Solution, LLC 2401 S Foothill Dr Ste D Salt Lake City, UT 84109-1479
Drugs	Cyanocobalamin 1 mg/mL/ Methionine 25 mg/mL/ Inositol 50 mg/mL/ Choline 50 mg/mL, 30 mL Multi-Dose Vial For Injection, Rx Only, Isomeric Pharmacy Solutions, 2401 Foothill Drive, SLC, UT 84109, Part # 1101, barcode 3 70285 11013 9	Class II	Lot #: 09018, Exp 04/17/17; 09023, Exp 04/22/17; 09024, Exp 04/23/17; 090 27, Exp 04/25/17; 09031, Exp 04/30/17; 10005, Exp 05/06/17; 10010, Exp 05/09/17; 11022, Exp 06/10/17; 11038, Exp 06/18/17; 11044, Exp 07/04/17; 120 03, Exp 07/08/17; 12010, Exp 07/12/17; 12021, Exp 07/30/17	Lack of Assurance of Sterility: due to concerns with production processes which cannot assure sterility of products intended to be sterile.	Isomeric Pharmacy Solution, LLC2401 S Foothill Dr Ste D Salt Lake City, UT 84109-1479
Drugs	Phenylephrine 2.5%, Tropicamide 1%, 15 mL Multi-Dose Ophthalmic (spelled Ophthalmic) Drops in a bottle, Rx Only, Isomeric Pharmacy Solutions, 2401 Foothill Dr, SLC, UT 84109, Part # 1300, barcode 3 70285 13001 4	Class II	Lot Numbers: 10003, Exp 04/05/17; 10018, Exp 04/17/17; 10023, Exp 04/23/17; 10025, Exp 04/24/17; 10027, Exp 04/29/17; 110 11, 11012, Exp 05/07/17; 11024, 11026, Exp 05/14/17; 11029, Exp 05/16/17; 11030, Exp 05/17/17; 110 32, Exp 05/21/17; 11045, Exp 06/04/17; 12008, Exp	Lack of Assurance of Sterility: due to concerns with production processes which cannot assure sterility of products intended to be sterile.	Isomeric Pharmacy Solution, LLC 2401 S Foothill Dr Ste D Salt Lake City, UT 84109-1479

Product Type	Product Description	Class	Code Information	Reason for Recall	Recalling Firm
			06/13/17; 12014, 12015, Exp 06/20/17; 12022, 12024, Exp 06/28/17		
Drugs	Testosterone Cypionate 200 mg/mL, Testosterone Propionate 20 mg/mL, 30 mL Multi-Dose Vial For Injection, Rx Only, Isomeric Pharmacy Solutions, 2401 Foothill Dr, SLC, UT 84109, Part # 1200, barcode 3 70285 12003 9.	Class II	Lot #: 09018, Exp 04/17/17; 09023, Exp 04/22/17; 09024, Exp 04/23/17; 09027, Exp 04/25/17; 09031, Exp 04/30/17; 10005, Exp 05/06/17; 10010, Exp 05/09/17; 11022, Exp 06/10/17; 11038, Exp 06/18/17; 11044, Exp 07/04/17; 12003, Exp 07/08/17; 12010, Exp 07/12/17; 12021, Exp 07/30/17	Lack of Assurance of Sterility: due to concerns with production processes which cannot assure sterility of products intended to be sterile.	Isomeric Pharmacy Solution, LLC 2401 S Foothill Dr Ste D Salt Lake City, UT 84109-1479
Drugs	Sulfamethoxazole and Trimethoprim Oral Suspension, USP 200 mg / 40 mg per 5 mL , Grape Flavor, Rx Only, 16 fl oz. (473 mL), HI-TECH PHARMACAL CO., INIC, Amityville, NY 11701, NDC 50383-824-16	Class II	Lot# 348913, Exp.01/18; Lot# 349552, Exp.03/18; Lot# 349681, Exp. 03/18; Lot# 349683, Exp. 03/18; Lot# 349685, Exp. 03/18; Lot# 349687, Exp. 03/18; Lot# 349689, Exp. 03/18; Lot# 350636, Exp.03/18	Failed Dissolution Specifications	Akorn Inc 1925 W Field Ct Lake Forest, IL 60045-4862
Drugs	Fluconazole Tablets, USP, 100 mg, 100-count Unit Dose carton, Rx only, Manufactured by Dr. Reddy's Laboratories Limited, Bachupally - 500 090 INDIA, Distributed by MAJOR PHARMACEUTICALS, 31778 Enterprise Dr., Livonia, MI 48150 USA, NDC 0904-6500-61	Class II	Lot#: T-00520, EXP 02-17, T-00632, T-00699, EXP. 04 -17	Failed Dissolution Specifications	The Harvard Drug Group 17177 N Laurel Park Dr Ste 233 Livonia, MI 48152-3951
Drugs	Fluconazole Tablets, USP, 200 mg, 100-count Unit Dose carton, Rx only, Manufactured by Dr. Reddy's Laboratories Limited, Bachupally - 500 090 INDIA, Distributed by MAJOR PHARMACEUTICALS, 31778 Enterprise Dr., Livonia, MI 48150 USA, NDC 0904-6501-61	Class II	Lot #:T-00519, Exp. 01-17	Failed Dissolution Specifications	The Harvard Drug Group 17177 N Laurel Park Dr Ste 233 Livonia, MI 48152-3951
Drugs	Clozapine Tablets USP, 25 mg, 100-count bottle (NDC 0093-4359-01), 500- count bottle (NDC 0093-4359-05), 100 Unit Dose Blisters per carton (NDC 0093-4359-93), Individual Blister Pack (NDC 0093-4359-19), Rx Only, Manufactured By: Teva Pharmaceutical Industries Ltd., Jerusalem, 9777600, Israel	Class II	100 (NDC 0093-4359-01) and 500 count bottles (NDC 0093-4359-05)- Lot # 07C160; Exp. 03/18 100 Unit Dose Blisters/Carton (NDC 0093-4359-93) and Individual Blister Pack (NDC 0093-4359-19) - Lot # 07C160A; Exp. 03/18	Microbial Contamination of Non-Sterile Products	Teva Pharmaceuticals USA1090 Horsham Rd North Wales, PA 19454-1505

Product Type	Product Description	Class	Code Information	Reason for Recall	Recalling Firm
Drugs	Buprenorphine HCl Injection, 0.3 mg/mL, 1 mL Single Dose Vial (NDC 42023-179-01), packaged in 1 mL x 5 Single Dose Vials per carton (NDC 42023-179-05), Rx Only, Distributed by: Par Pharmaceuticals Companies, Inc., Spring Valley, NY 10977.	Class II	Lot #: 821102, 821103, Exp 01/18; 821104, 821106, 821107, Exp 02/18; 821108, Exp 03/18; 821884, 821885, Exp 07/18; 821886, 821887, Exp 08/18; 822767, Exp 09/18; 824183, Exp 10/18.	Crystallization: due to the presence of white, crystalline particulates, adhered to the side and bottom of the glass vials, which are comprised of principally dextrose and the buprenorphine active component.	PAR Sterile Products LLC870 Parkdale Rd Rochester, MI 48307-1740
Drugs	Olanzapine Tablets, 2.5 mg, 1000-count bottles, Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389 350, Gujarat, India, NDC 62756-551-18	Class III	Lot #: JKP2751A, Exp 05/17; JKR5048A, Exp 04/18	Failed Impurities/Degradation Specifications: out of specification results for the related substances test parameter (impurities).	Sun Pharmaceutical Industries, Inc.270 Prospect Plains Rd Cranbury, NJ 08512-3605
Drugs	PrednisolONE Oral Solution USP, 15 mg/5mL, alcohol content: 5%(v/v) 240 mL bottle, Rx Only, Manufactured in Canada By: CONTRACT PHARMACEUTICALS LIMITED CANADA, Ontario, Canada, L5N 6L6, Manufactured For: TEVA PHARMACEUTICALS USA, Sellersville, PA 18960, NDC 0093-6118-87	Class III	Lot # 94358; Exp. 05/17 Lot # 94920A; Exp. 07/17 Lot # 97083A; Exp. 12/17	Failed Stability Specifications	Teva Pharmaceuticals USA1090 Horsham Rd North Wales, PA 19454-1505
Drugs	Mozobil (plerixafor injection) 24mg/1.2mL (20mg/mL), For Single Use Only, Rx Only, Manufactured by: Genzyme Corporation 500 Kendall Street, Cambridge, MA 02412 USA NDC: 0024-5862-01	Class III	Lot #: 5RZ001C, 5RZ001D; Exp. 04/18	Labeling: Incorrect or Missing Package Insert	Sanofi-Aventis U.S. LLC55 Corporate Dr Bridgewater, NJ 08807-1265
Drugs	IC-Green (indocyanine green for injection, USP), 25 mg, packaged in a kit containing six vials of 25 mg lyophilized powder, Rx only, Manufactured by: Akorn, Inc., NDC 17478-701-02	Class III	Kit Lot #031126; Exp 8/20 18	Product is being recalled due to low pH value.	Akorn, Inc. 1925 W Field Ct Ste 300 Lake Forest, IL 60045-4862
Drugs	Olanzapine Tablets, 7.5 mg, packaged in a) 30-count bottles (NDC 62756-553-83), b) 100-count bottles (NDC 62756-553-88), and c) 1000-count bottles (NDC 62756-553-18), Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc.,	Class III	Lot #: a) JKP3150B, Exp 06/17, JKR5749A, Exp 06/18 ; b) JKP2757A, Exp 05/17, JKP3149A, JKP3150A, Exp 06/17, JKR5049A, Exp 04/18; c) JKP2758B, Exp 05/17	Failed Impurities/Degradation Specifications: out of specification results for the related substances test parameter (impurities).	Sun Pharmaceutical Industries, Inc.270 Prospect Plains Rd Cranbury, NJ 08512-3605

Product Type	Product Description	Class	Code Information	Reason for Recall	Recalling Firm
	Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389, 350 Gujarat, India.		7		
Drugs	Olanzapine Tablets, 10 mg, packaged in a) 30-count bottles (NDC 62756-554-83), b) 100-count bottles (NDC 62756-554-88), and c) 1000-count bottles (NDC 62756-554-18), Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389, 350 Gujarat, India, NDC 62756-551-18.	Class III	Lot #: a) JKP1354A, Exp 03/17, JKP2746A, Exp 06/17, JKR5751A, Exp 04/18; b) JKP1355A, Exp 03/17, JKP2738A, JKP3145A, Exp 06/17, JKR5476A, Exp 04/18; c) JKP1353A, Exp 03/17, JKP3146A, JKP2746B, Exp 06/17	Failed Impurities/Degradation Specifications: out of specification results for the related substances test parameter (impurities).	Sun Pharmaceutical Industries, Inc270 Prospect Plains Rd Cranbury, NJ 08512-3605
Drugs	Olanzapine Tablets, 20 mg, packaged in a) 30-count bottles (NDC 62756-556-83), b) 100-count bottles (NDC 62756-556-88), and c) 1000-count bottles (NDC 62756-556-18), Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389, 350 Gujarat, India.	Class III	Lot #: a) JKR5759A, Exp 04/18; b) JKP0943A, Exp 04/17, JKR5520A, Exp 04/18; c) JKP0988A, Exp 04/17	Failed Impurities/Degradation Specifications: out of specification results for the related substances test parameter (impurities).	Sun Pharmaceutical Industries, Inc270 Prospect Plains Rd Cranbury, NJ 08512-3605
Drugs	Isopto Carpine (pilocarpine hydrochloride ophthalmic solution) 4%, packaged in 15 mL bottle, Rx only, Manufactured by: Alcon Laboratories, Inc. Fort Worth Texas 76134 USA NDC 0998-0206-15	Class III	Lot #: 244661F, Exp. Feb 2 018	Failed Impurities/Degradation Specifications.	Novartis Pharmaceuticals Corp. 1 Health Plz East Hanover, NJ 07936-1016
Drugs	Pilocarpine Hydrochloride Ophthalmic Solution 4% , packaged in 15 mL bottles, Rx Only, Manufactured by Alcon Laboratories, Inc. Fort Worth, Texas 76134 Sandoz Princeton, NJ 08540, NDC 61314-206-15	Class III	Lot #: 244660F, Exp. FEB 2 018	Failed Impurities/Degradation Specifications.	Novartis Pharmaceuticals Corp. 1 Health Plz East Hanover, NJ 07936-1016
Drugs	CLENZIderm M.D. Pore Therapy Salicylic Acid 2% Acne Treatment 5 fl. oz. (148 mL), Valeant Pharmaceuticals North America LLC Distributed by OMP, Inc Long Beach, CA 90806 Made in USA. Product SKU 301876102042, NDC 0187-6102-04	Class III	Lot #: 15J1277, Exp. 04/2017	Discoloration	Valeant Pharmaceuticals North America LLC 400 Somerset Corporate Blvd Bridgewater, NJ 08807-2867

Product Type	Product Description	Class	Code Information	Reason for Recall	Recalling Firm
Drugs	CLENZiderm M.D. Acne Treatment System, kit has 3 bottles a) Therapeutic Lotion (benzoyl peroxide 5% Acne Treatment) 47mL bottle, b) Daily Care Foaming Cleanser (Salicylic Acid 2% Acne Treatment) 118 mL bottle, c) Salicylic Acid 2% Acne Treatment 148mL, Valeant Pharmaceuticals North America LLC Distributed by OMP, Inc LongBeach, CA 90806 Made in USA, Product SKU 301876103018, NDC 0187-6103-01	Class III	Lot #: a) 15I1234, Exp. 09/18, b) 15E1221, Exp. 09/18, c) 15G1235 and 15I1236, Exp. 09/18	Discoloration	Valeant Pharmaceuticals North America LLC 400 Somerset Corporate Blvd Bridgewater, NJ 08807-2867
Drugs	Diphenhydramine HCl 25 mg, Softgel Gelatin Capsule, 15,000-count bulk drums, aenova/Swiss Caps USA, Inc., 14193 S.W. 119th Avenue, Miami, FL 33186, Product Code MSU0048P, NDC 6897080284	Class III	Batch #: 1404811, 1409802, 1502817, 1504808, 1509810, 1511802, 1603801, Exp. 12/12/2018	Subpotent	InnovaGel14193 Sw 119th Ave Miami, FL 33186-6013
Drugs	Dye Free Allergy Softgel Gelatin Capsule, 15,000-count bulk drums, aenova/Swiss Caps USA, Inc., 14193 S.W. 119th Avenue, Miami, FL 33186, Product Code MSU0067P, NDC 6897080284	Class III	Batch #: 1508803,1602801, 1602802, 1604801, 1604802, 1606801, 1606802, 1606803, 1606804, Exp. 08/03/2018	Subpotent	InnovaGel14193 Sw 119th Ave Miami, FL 33186-6013
Drugs	Donepezil HCl tablets, 10mg, packaged in 10x10 blister packs per carton (100 Unit Dose) container, Rx only, Manufactured by Sandoz, Inc., 506 Carnegie Center, Suite 400, Princeton, NJ 08805, Distributed by: McKesson Packaging Services, 7101 Weddington Rd, Concord, NC 28027, NDC 63739-678-10	Class III	Lot #0111593, Exp. 05/2017	Subpotent: Out of Specification result for assay test during routine stability testing.	McKesson Packaging Services7101 Weddington Rd NW Concord, NC 28027-3412
Drugs	Allergy Relief Diphenhydramine HCl 25 mg, Antihistamine, Dye-Free, 24 Softgels, distributed under the following labels: (a) TopCare Allergy Relief, DISTRIBUTED BY TOPCO ASSOCIATES LLC, ELK GROVE VILLAGE, IL 60007, NDC 36800-483-24, UPC 0-36800-39134-5; (b) Rexall Since 1903 Allergy Relief, PACKAGED FOR DOLGENCORP, LLC, 100 MISSION RIDGE GOODLETTSVILLE, TN 37072, UPC	Class III	Lot #: a) A01542, A03660, A04300, A04930, Exp 03/19; A05484, A07951, A12448, Exp 07/19; Y93105, Exp 02/19; b) A04938, Exp 03/19; A08149, A12621, Exp 07/19; c) A06557, A13030, Exp 03/19; d) A00239, Exp 03/19; A05180, A09906, Exp 07/19; Y83246, Y87531, Y87680, Exp 08/18; Y91225, Y92670, Y98200, Y98674, Exp 02/19	Subpotent: This product is being recalled due to low out of specification assay results at the 9 month time point.	P & L Development, LLC 200 Hicks St Westbury, NY 11590-3323

Product Type	Product Description	Class	Code Information	Reason for Recall	Recalling Firm
Drugs	Zinc Oxide Paste 25%, 500 g, For Prescription Compounding, Fagron Inc. 2400 Pilot Knob Rd, St. Paul, MN 55120m NDC 51522-0694-5.	Class III	Lot #: 17C01-U07-036096, Exp. 5/1/2020	Labeling: Error on Declared Strength: Error is due to an incorrect value in the Drug Facts Panel. The correct strength is displayed on the primary container.	Fagron, Inc 2400 Pilot Knob Rd Saint Paul, MN 55120-1118
Drugs	Aripiprazole Tablets, 2 mg, 30 count unit dose box, Rx only, Manufactured by Apotex Inc., Toronto, Ontario, Canada, Distributed by Major Pharmaceuticals, Livonia, MI NDC 0904-6509-04	Class III	LOT: T-00601 Exp: 04-2017	Superpotent Drug; out of specification results for assay (manufacturer)	The Harvard Drug Group 17177 N Laurel Park Dr Ste 233 Livonia, MI 48152-3951

*Please refer to FDA website for further information; <http://www.fda.gov/Safety/Recalls/EnforcementReports/default.htm>

CURRENT DRUG SHORTAGES

Rabies Vaccine

April 20, 2017

Reason for the Shortage

- GlaxoSmithKline Vaccines could not provide a reason for the RabAvert shortage.

Estimated Resupply Dates

- GlaxoSmithKline Vaccines has RabAvert on back order and the company estimates a release date in May 2017. Emergency stock is available if a patient has been exposed.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=959>

Topotecan Capsules

April 24, 2017

Reason for the Shortage

- Novartis did not provide a reason for the current shortage.

Estimated Resupply Dates

- Novartis has Hycamtin 0.25 mg capsules available with an expiration date of December 2017. Hycamtin 1 mg capsules are available with an expiration date of January 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1266>

Morrhuate Sodium Injection

April 24, 2017

Reason for the Shortage

- American Regent has morrhuate sodium injection on shortage due to manufacturing delays.

Estimated Resupply Dates

- American Regent has morrhuate sodium 50 mg/mL 30 mL vials on back order and the company cannot estimate a release date

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=903>

Methyldopate Injection

April 24, 2017

Reason for the Shortage

- American Regent has methyldopate injection on shortage due to manufacturing delays.
- There are no other suppliers of methyldopate injection.

Estimated Resupply Dates

- American Regent has methyldopate injection on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=844>

Electrolyte Concentrate

April 24, 2017

Reason for the Shortage

- American Regent has Nutrilite and Nutrilite II on back order due to manufacturing delays

Estimated Resupply Dates

- American Regent has Nutrilite and Nutrilite II presentations on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1054>

Talc, Sterile

April 25, 2017

Reason for the Shortage

- Lymol has Sclerosol and talc powder on shortage due to manufacturing delays.¹
- There are no other commercially available suppliers of sterile talc.

Estimated Resupply Dates

- Lymol has Sclerosol and talc powder on long-term back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1248>

Asparaginase *Erwinia chrysanthemi*

April 25, 2017

Reason for the Shortage

- Jazz Pharmaceuticals had Erwinaze on shortage due to manufacturing issues.

Estimated Resupply Dates

- Jazz Pharmaceuticals has Erwinaze available. The company requests that Erwinaze only be ordered for patients who are currently undergoing treatment or initiating treatment.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1252>

Fludarabine Injection

April 27, 2017

Reason for the Shortage

- Actavis has fludarabine available.
- Fresenius Kabi has fludarabine on shortage due to increased demand.
- Pfizer has fludarabine on shortage due to increased demand.
- Sagent has fludarabine 25 mg/mL 2 mL vials on shortage due to manufacturing delays.

Estimated Resupply Dates

- Pfizer has fludarabine lyophilized powder 50 mg vials on back order and the company estimates a release date of late-June 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=648>

Yellow Fever Vaccine Injection

April 30, 2017

Reason for the Shortage

- Sanofi Pasteur could not provide a reason for the shortage of YF-Vax.1
- There are no other suppliers of yellow fever vaccine.
- Additional information on the yellow fever shortage.
- FDA accepted an investigational new drug application in October 2016. This is for the importation of another yellow fever vaccine from France. The trade name of the imported product is Stamaril. The initial rollout began in April 2017.
- Information on countries that require yellow fever vaccination

Estimated Resupply Dates

- Sanofi Pasteur has YF-Vax multi-dose vials and single dose vials available in limited supply but product is expected to be depleted soon. Customers can call Sanofi Pasteur to order product for patients traveling in the next 30 days.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=383>

Succinylcholine Injection

April 30, 2017

Reason for the Shortage

- Pfizer did not provide a reason for the shortage.

Estimated Resupply Dates

- Pfizer has Quelicin 20 mg/mL 10 mL vials on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1267>

Papaverine Injection

April 30, 2017

Reason for the Shortage

- American Regent did not provide a reason for the shortage.

Estimated Resupply Dates

- American Regent has papaverine 30 mg/mL 2 mL vials available in limited supply.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=781>

Nitroglycerin Injection

April 30, 2017

Reason for the Shortage

- American Regent did not provide a reason for the shortage.
- The premixed bags are not affected by this shortage

Estimated Resupply Dates

- American Regent has nitroglycerin 50 mg/mL 10 mL vials on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=786>

Hydroxyzine Hydrochloride Injection

April 30, 2017

Reason for the Shortage

- American Regent would not provide a reason for the shortage. They are the sole supplier of hydroxyzine injection.

Estimated Resupply Dates

- American Regent has hydroxyzine 25 mg/mL 1 mL vials, 50 mg/mL 2mL vials, and 50 mg/mL 1 mL and 10 mL vials on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1185>

Erythromycin Lactobionate Injection

April 30, 2017

Reason for the Shortage

- Pfizer has Erythrocine on shortage due to manufacturing delays.

Estimated Resupply Dates

- Pfizer has Erythrocine 500 mg ADD-Vantage vials on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=546>

Dexpanthenol Injection

April 30, 2017

Reason for the Shortage

- American Regent has dexpanthenol injection on shortage due to manufacturing delays.
- There are no other suppliers of dexpanthenol injection

Estimated Resupply Dates

- American Regent has dexpanthenol injection on long-term back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1103>

Torsemide Injection

May 2, 2017

Reason for the Shortage

- Roche discontinued Demadex injection for business reasons. Demadex tablets are not affected by this shortage.
- American Regent has torsemide on shortage due to manufacturing delays

Estimated Resupply Dates

- American Regent has torsemide injection on long-term back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=344>

Procainamide Hydrochloride Injection

May 2, 2017

Reason for the Shortage

- Pfizer did not provide a reason for the shortage.

Estimated Resupply Dates

- Pfizer has procainamide 500 mg/mL 2 mL vials on back order and the company estimates a release date of 3rd quarter 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=868>

Lidocaine Hydrochloride Oral Topical Solution (Viscous) 2%

May 2, 2017

Reason for the Shortage

- Akorn has viscous lidocaine available.
- West-Ward did not provide a reason for the viscous lidocaine shortage

Estimated Resupply Dates

- West-Ward has viscous lidocaine 100 mL bottles on back order and the company estimates a release date in mid-April 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1171>

Levocarnitine Oral Tablets and Solution

May 2, 2017

Reason for the Shortage

- Akorn has levocarnitine tablets available.
- Sigma-Tau has Carnitor presentations on shortage due to increased demand.
- Rising Pharmaceuticals discontinued levocarnitine tablets in January 2017

Estimated Resupply Dates

- Akorn has levocarnitine oral solution on back order and the company estimates a release date in mid-May 2017.
- Sigma-Tau has Carnitor 100 mg/mL oral solution and Carnitor SF 100 mg/mL Sugar-Free oral solution on allocation

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1254>

loversol Injection

May 2, 2017

Reason for the Shortage

- Guerbet could not provide a reason for the Optiray shortage.

Estimated Resupply Dates

- Guerbet had most Optiray products on allocation. However, the company did not provide updated availability information.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1253>

Dextrose (50%) Injection

May 2, 2017

Reason for the Shortage

- Amphastar has 50% dextrose injection on shortage due to increased demand.
- Pfizer has 50% dextrose injection on shortage due to manufacturing delays.

Estimated Resupply Dates

- Amphastar has limited supply of 50% dextrose 50 mL syringes.

- Pfizer has 50% dextrose 50 mL LifeShield syringes on back order and the company estimate a release date of mid-June 2017. The 50 mL vials are on back order and the company estimates a release date of late-June 2017. Pfizer has 50% dextrose 50 mL Ansyf syringes on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1012>

Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection

May 2, 2017

Reason for the Shortage

- Pfizer has Precedex 50 mL and 100 mL premixed bottles on shortage due to manufacturing delay.
- Dexmedetomidine 100 mcg/mL vials are not affected by this shortage.

Estimated Resupply Dates

- Pfizer has Precedex 4 mcg/mL 20 mL vials and 50 mL premixed bottles on back order and the company estimates a release date of mid-May 2017 for the 20 mL vials and early-May 2017 for the 50 mL bottles.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1263>

Cisplatin Injection

May 2, 2017

Reason for the Shortage

- Fresenius Kabi did not provide a reason for the shortage.
- Mylan Institutional could not provide a reason for the shortage.
- Teva has cisplatin available.
- WG Critical Care has cisplatin available

Estimated Resupply Dates

- Fresenius Kabi has cisplatin 100 mL vials on back order and the company estimates a release date of mid-May 2017
- Mylan Institutional has cisplatin 50 mL and 100 mL vials temporarily unavailable and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=57>

Ciprofloxacin Oral Suspension

May 2, 2017

Reason for the Shortage

- Lupin did not provide a reason for the shortage.
- Bayer has Cipro oral suspension available.

Estimated Resupply Dates

- Lupin has ciprofloxacin oral suspension on long-term back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1247>

Carboplatin Solution for Injection

May 2, 2017

Reason for the Shortage

- Bedford discontinued carboplatin in May, 2011 to concentrate on the manufacturing of other products.
- Fresenius Kabi has carboplatin available.

- Mylan Institutional cannot provide a reason for the shortage.
- Pfizer has carboplatin injection available.
- Sagent states the reason for the shortage is increased demand for the product and manufacturing delays.
- Sandoz has discontinued carboplatin injection.
- Teva has carboplatin available

Estimated Resupply Dates

- Mylan Institutional has all carboplatin injection on back order and the company cannot estimate a release date.
- Sagent has carboplatin 5 mL, 15 mL, 45 mL, and 60 mL vials on back order and the company cannot estimate a release date
-

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1005>

Atropine Sulfate Injection

May 2, 2017

Reason for the Shortage

- American Regent did not provide a reason for the shortage of atropine injection.
- Pfizer states the shortage was due to manufacturing delays.

Estimated Resupply Dates

- American Regent has atropine 0.4 mg/mL 1 mL ampules and 1 mg/mL 1 mL vials on back order and the company cannot estimate a release date.
- Pfizer has atropine 0.05 mg/mL 5 mL Ansyr syringes on back order and the company estimates a release date of 2nd quarter 2017. The 0.1 mg/mL 10 mL LifeShield syringes are on back order and the company estimates a release date of mid-June 2017. The 0.1 mg/mL 5 mL LifeShield syringes are on back order and the company estimates a release date of late-July 2017. The 0.1 mg/mL 10 mL Ansyr syringes are on back order and the company estimates a release date of mid-May 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=814>

Tobramycin Injection

May 3, 2017

Reason for the Shortage

- Akorn has tobramycin injection on shortage due to manufacturing delays.
- Pfizer did not provide a reason for the shortage.

Estimated Resupply Dates

- Akorn has tobramycin 40 mg/mL 2 mL vials on back order and the company cannot estimate a release date.
- Pfizer has tobramycin 40 mg/mL 2 mL vials on back order with an estimated release of mid-June 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=701>

Multiple Vitamins for Infusion

May 3, 2017

Reason for the Shortage

- Pfizer states the shortage is due to manufacturing delays.
- Baxter has all presentations fully available at this time.

Estimated Resupply Dates

- Pfizer has M.V.I. adult 5 mL Dual vials on back order and the company estimates a release date of early-May 2017.

- Pfizer has M.V.I. pediatric 5 mL vials on back order and the company estimates a release date of 4th quarter 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=831>

Mitoxantrone Hydrochloride Injection

May 3, 2017

Reason for the Shortage

- Fresenius Kabi had mitoxantrone on shortage due to increased demand.
- Pfizer has mitoxantrone injection on shortage due to manufacturing delays
- Teva had mitoxantrone injection on allocation due to current market conditions.

Estimated Resupply Dates

- Pfizer has all mitoxantrone presentations on long-term back order and the company estimates a release date of early-4th quarter 2017.
- Teva has mitoxantrone 10 mL vials temporarily unavailable and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1212>

Labetalol Injection

May 3, 2017

Reason for the Shortage

- Akorn has labetalol injection on shortage due to increased demand.
- Pfizer has labetalol injection on shortage due to manufacturing delays.
- West-Ward has labetalol injection available

Estimated Resupply Dates

- Akorn has labetalol 5 mg/mL 20 mL and 40 mL vials on back order and the company estimates a release date of late-May 2017 for the 20 mL vials and cannot estimate a release date for the 40 mL vials.
- Pfizer has labetalol 5 mg/mL 20 mL vials on allocation. The 40 mL vials are on back order and the company estimates a release date of June 2017. The 5 mg/mL 4 mL syringes are on back order and the company estimates a release date of early-May 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=397>

Dopamine Hydrochloride Injection

May 3, 2017

Reason for the Shortage

- American Regent has dopamine on shortage due to manufacturing delays.
- Baxter could not provide a reason for the shortage.
- Pfizer states the shortage is due to manufacturing delays.

Estimated Resupply Dates

- American Regent has all dopamine presentations on back order and the company cannot estimate a release date.
- Pfizer has dopamine 40 mg/mL 10 mL vials on back order and the company estimates a release date of 3rd quarter 2017. The dopamine 400 mg/250 mL premixed bags are on back order and the company estimates a release date of early-May 2017. The dopamine 800 mg/500 mL premixed bags are on back order and the company estimates a release date of late-May 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1243>

Ceftazidime Injection

May 3, 2017

Reason for the Shortage

- Pfizer has Tazicef on shortage due to increased demand.
- Sagent has ceftazidime injection on shortage due to manufacturing delays.
- Sandoz discontinued ceftazidime 1 gram and 2 gram vials in 2015.
- BBraun had ceftazidime on allocation due to increased demand.
- WG Critical Care has ceftazidime on shortage due to manufacturing delays.

Estimated Resupply Dates

- Sagent has ceftazidime 1 gram, 2 gram, and 6 gram vials on allocation.
- Teligent has Fortaz 1 gram, 2 gram, and 6 gram vials on back order and the company estimates a release date of early-May 2017 for the 1 gram vials and cannot estimate a release date for the 2 gram and 6 gram vials.
- WG Critical Care has ceftazidime 1 gram, 2 gram, and 6 gram vials on back order and the company estimates a release date of June 2017 for the 2 gram vials and July 2017 for the 1 gram and 6 gram vials.
- Pfizer has Tazicef 1 gram and 2 gram ADD-Vantage vials on back order and the company estimates a release date of mid-June 2017 for the 1 gram vials and late-June 2017 for the 2 gram vials. The 2 gram and 6 gram vials are on back order and the company estimates a release date of early-May 2017 for the 2 gram vials and mid-May 2017 for the 6 gram vials.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=869>

Epinephrine Injection

May 4, 2017

Reason for the Shortage

- Amphastar will stop distributing epinephrine 1 mg/mL 30 mL vials on May 10, 2017. They are continuing to supply 0.1 mg/mL 10 mL syringes. These are on shortage due to increased demand.
- Pfizer will stop distributing epinephrine 1 mg/mL presentations on May 10, 2017.
- BPI has epinephrine 1 mg/mL 2 mL ampules available.
- Par has Adrenalin 1 mg/mL 1 mL and 30 mL vials available.

Estimated Resupply Dates

- Amphastar has epinephrine 0.1 mg/mL 10 mL syringes on allocation.
- Pfizer has epinephrine 0.1 mg/mL 10 mL syringes on back order and the company estimates a release date of late-May 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=685>

Bupivacaine Injection

May 4, 2017

Reason for the Shortage

- AuroMedics has not provided a reason for the shortage.
- Fresenius Kabi has Sensorcaine on shortage due to increased demand for the product.
- Pfizer has bupivacaine on shortage due to manufacturing delays.

Estimated Resupply Dates

- Fresenius Kabi has 0.25% Sensorcaine preservative-free 30 mL vials in sterile packs on back order and the company estimates a release date of early-May 2017.

- Pfizer has 0.25% bupivacaine 50 mL vials on back order and the company estimates a release date of early-June 2017. The 0.5% bupivacaine 50 mL vials are on allocation.
- Pfizer has 0.5% Marcaine 10 mL preservative-free vials on back order and the company estimates a release date of late-May 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=864>

5% Dextrose Injection (PVC-free and DEHP-free)

May 4, 2017

Reason for the Shortage

- ICU Medical states the shortage is due to increased demand and manufacturing delays. ICU Medical discontinued the 500 mL VisiV bags in 2011 due to leaking around the administration and medications ports.
- ICU Medical is now the IV fluid business of Pfizer after the acquisition of Hospira.
- Baxter did not provide a reason for the shortage.
- BBraun has 250 mL, 500 mL, and 1,000 mL PVC/DEHP-free bags on allocation. The company is not adding any new allocations at this time.

Estimated Resupply Dates

- BBraun has 5% dextrose 250 mL, 500 mL, and 1,000 mL PVC/DEHP-free bags on allocation.
- Baxter has 5% dextrose 250 mL and 500 mL PVC/DEHP-free bags on back order and the company cannot estimate a release date
- ICU Medical has 5% dextrose 250 mL PVC/DEHP-free bags on intermittent back order and the company is releasing product as it becomes available.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1269>

5% Dextrose Injection

May 4, 2017

Reason for the Shortage

- Pfizer states the shortage is due to increased demand and manufacturing delays.
- Baxter did not provide a reason for the shortage.
- 5% dextrose 1,000-mL bags are not affected at this time.

Estimated Resupply Dates

- ICU Medical has 5% dextrose 250 mL ADD-Vantage products on back order. The flexible containers are on intermittent back order and the company is releasing product as it is available. The company estimates a release date of late-May for the regular ADD-Vantage bags.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1268>

Vancomycin Hydrochloride Injection

May 5, 2017

Reason for the Shortage

- Pfizer has vancomycin bulk vials on back order due to manufacturing delays. All other presentations are available.
- Fresenius Kabi has vancomycin injection on shortage due to increased demand.
- Mylan Institutional has vancomycin injection available
- Baxter could not provide a reason for the shortage of vancomycin 500 mg/100 mL frozen premixed bags. All other presentations are available.
- Sagent has vancomycin injection on shortage due to manufacturing delays.

Estimated Resupply Dates

- Fresenius Kabi has vancomycin 10 gram vials on intermittent back order with regular releases.
- Sagent has vancomycin 10 gram vials on back order and the company estimates a release date of May 2017. The 5 gram vials are on allocation.
- Baxter has vancomycin 500 mg/100 mL frozen premixed bags in 6 count on back order and the company cannot estimate a release date. Vancomycin 500 mg/100 mL frozen premixed bags in 12 count are available in limited quantities.
- Pfizer has vancomycin lyophilized powder 5 gram vials on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=132>

Piperacillin Tazobactam Injection

May 5, 2017

Reason for the Shortage

- Apotex has piperacillin/tazobactam on shortage due to regulatory delays.
- AuroMedics and Sandoz could not provide a reason for the shortage.
- Baxter has Zosyn frozen premixes on allocation due to increased demand.
- Fresenius Kabi has piperacillin/tazobactam on shortage due to increased demand.
- Mylan Institutional launched piperacillin/tazobactam 3.375 gram and 4.5 gram vials in early-June 2016.
- Pfizer has Zosyn on shortage due to manufacturing delays.
- Sagent has piperacillin/tazobactam on shortage due to increased demand.
- Sandoz has piperacillin/tazobactam available for contracted customers.
- WG Critical Care states the reason for the shortage is increased demand.
- FDA in conjunction with SteriMax was allowing temporary importation of piperacillin/tazobactam 3.375 gram, 4.5 gram, and 40.5 gram vials from Canada. This was being distributed through X-Gen Pharmaceuticals. These are no longer being imported with the launch of the products from X-Gen. The product codes on these items will not be recognized by U.S. systems so institutions will need to implement alternative plans to assure the dose is being given correctly. More information can be found here on the FDA site.
- X-Gen recently launched piperacillin/tazobactam injection.

Estimated Resupply Dates

- Apotex has piperacillin/tazobactam 2.25 gram, 3.375 gram, 4.5 gram, and 40.5 gram vials on back order and the company estimates a release date of late-June 2017.
- AuroMedics has piperacillin/tazobactam on intermittent back order and the company is releasing product as it becomes available. Check wholesalers for inventory.
- Baxter has all frozen piperacillin/tazobactam presentations available in limited supply.
- Fresenius Kabi has piperacillin/tazobactam 2.25 gram, 4.5 gram, and 40.5 gram vials on back order and the company estimates a release date of mid- to late-June 2017 for the 2.25 gram vials, late-May to early-June 2017 for the 4.5 gram vials and early-May 2017 for the 40.5 gram vials.
- Pfizer has piperacillin/tazobactam 2.25 gram vials, 3.375 gram, 4.5 gram, and 40.5 gram vials on allocation. The 2.25 gram ADD-Vantage vials, and 4.5 gram ADD-Vantage vials are on allocation. The 3.375 gram ADD-Vantage vials are on back order and the company estimates a release date of late-May 2017.
- Pfizer has Zosyn 2.25 gram vials, 3.375 gram vials, 4.5 gram vials, and 40.5 gram vials on back order and the company estimates a release date of January 2018.
- Sagent has piperacillin/tazobactam 3.375 gram and 4.5 gram vials on allocation.
- Sandoz has piperacillin/tazobactam 2.25 gram (NDC 00781-3344-95), 3.375 gram (NDC 00781-3350-95), and 4.5 gram (NDC 00781-3367-95) vials on back order and the company cannot estimate a release date.
- WG Critical Care has piperacillin/tazobactam 2.25 gram, 3.375 gram, 4.5 gram, and 40.5 gram vials on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1075>

Ofloxacin Ophthalmic Solution

May 5, 2017

Reason for the Shortage

- Allergan has Ocuflax ophthalmic solution available.
- Akorn did not provide a reason for the shortage.
- Rising has ofloxacin ophthalmic solution available.
- Valeant did not provide a reason for the shortage.

Estimated Resupply Dates

- Valeant has temporarily discontinued ofloxacin ophthalmic solution in 5 mL and 10 mL bottles and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1235>

Octreotide Injection

May 5, 2017

Reason for the Shortage

- Fresenius Kabi did not provide a reason for the shortage.
- Mylan Institutional has octreotide available.
- Sagent has octreotide on shortage due to manufacturing delays.
- Sun Pharma refuses to provide availability information at this time.
- Teva has octreotide available.
- Novartis has Sandostatin available.

Estimated Resupply Dates

- Fresenius Kabi has octreotide 50 mcg/mL 1 mL vials on back order and the company estimates a release date of 1st quarter 2018.
- Sagent has octreotide 50 mcg/mL 1 mL vials and 500 mcg/mL 1 mL vials on back order and the company estimates a release date of July for the 50 mcg/mL vials and June 2017 for the 500 mcg/mL 1 mL vials.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=803>

Morphine Injections

May 5, 2017

Reason for the Shortage

- Astramorph injection has been unavailable since 2012. Fresenius Kabi changed manufacturing sites and cannot estimate if Astramorph will return.
- Pfizer states the shortage is due to manufacturing delays. Pfizer discontinued morphine ADD-Vantage vials in January 2017.
- West-Ward launched several new morphine sulfate products in late-September 2015. They are not actively marketing the 15 mg/mL 1 mL vials or the 8 mg/mL 1 mL vials (NDC 00641-6075-25). They are still marketing the 8 mg/mL 1 mL vials with NDC 00641-6126-25.

Estimated Resupply Dates

- West-Ward has Infumorph 10 mg/mL 20 mL preservative-free vials on back order and the company cannot estimate a release date. Duramorph 0.5 mg/mL 10 mL preservative-free ampules are on back order and the company estimates a release date of mid-May to early-June 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=664>

Leuprolide Acetate 14-Day Kit

May 5, 2017

Reason for the Shortage

- Caraco will not provide availability information.
- Sandoz states the reason for the shortage was increased demand.
- Teva states the shortage is due to manufacturing delays

Estimated Resupply Dates

- Teva has leuprolide acetate injection on long-term back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=737>

Cefoxitin Sodium Injection

May 5, 2017

Reason for the Shortage

- Fresenius Kabi and West-Ward did not provide a reason for the shortage.
- Sagent has cefoxitin on shortage due to manufacturing delays.
- BBraun has cefoxitin on allocation due to increased demand

Estimated Resupply Dates

- BBraun has cefoxitin 2 gram premixes on back order and the company cannot estimate release date. Check wholesalers for inventory.
- Fresenius Kabi has cefoxitin 1 gram vials on back order and the company estimates a release date of early-June 2017.
- Sagent has cefoxitin 10 gram vials on back order and the company estimates a release date of May 2017.
- West-Ward has cefoxitin 1 gram, 2 gram, and 10 gram vials on back order and the company estimates a release date of June or July 2017 for the 1 gram and 2 gram vials and cannot estimate a release date for the 10 gram vials.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1256>

Cefepime Injection

May 5, 2017

Reason for the Shortage

- Apotex could not provide a reason for the shortage.
- Baxter had cefepime on shortage due to increased demand.
- BBraun has cefepime on shortage due to increased demand.
- Fresenius Kabi has cefepime injection on shortage due to manufacturing delays.
- Pfizer has Maxipime on shortage due to manufacturing delays.
- Sagent has cefepime injection on shortage due to manufacturing delays.
- Sandoz discontinued cefepime injection in early-2016.
- WG Critical Care had cefepime injection on shortage due to increased demand

Estimated Resupply Dates

- Apotex has cefepime 1 gram vials in 1 count on back order and the company cannot estimate a release date. The 1 gram vials in 10 count and 2 gram vials in 10 count are available in limited supply.
- BBraun has cefepime 1 gram premixed bags on back order and the company cannot estimate a release date.
- Fresenius Kabi has cefepime 1 gram vials on back order and the company estimates a release date of early-June 2017.

- Pfizer has Maxipime 1 gram vials on back order and the company estimates a release date of late-June 2017. The 2 gram vials are on back order and the company estimates a release date of June 2017. The 1 gram ADD-Vantage vials are on back order and the company estimates a release date of July 2017. The 2 gram ADD-Vantage vials are on back order and the company estimates a release date of August 2017.
- Sagent has cefepime 1 gram vials on back order and the company estimates a release date of June 2017. The 2 gram vials are on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1176>

Amoxicillin and Clavulanate 1000 mg/62.5 mg Extended-Release Tablets

May 5, 2017

Reason for the Shortage

- Dr. Reddy's states they are having raw ingredient issues.
- Sandoz did not provide a reason for the shortage.

Estimated Resupply Dates

- Dr. Reddy's has Augmentin XR and generic amoxicillin/clavulanate 1000 mg / 62.5 mg tablets on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1259>

Albuterol Inhalation Solution

May 5, 2017

Reason for the Shortage

- Nephron had albuterol 0.5% unit-of-use vials on shortage. The other strengths and sizes of albuterol inhalation solution are not affected at this time.

Estimated Resupply Dates

- Nephron has albuterol 2.5 mg/0.5 mL unit-of-use vials available.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1264>

Acetazolamide Injection

May 5, 2017

Reason for the Shortage

- West-Ward has acetazolamide injection available.
- Sagent sold acetazolamide injection to Mylan Institutional in early 2017.
- X-Gen has acetazolamide injection available.

Estimated Resupply Dates

- All marketed presentations are available.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=463>

Sodium Phosphate Injection

May 8, 2017

Reason for the Shortage

- American Regent has sodium phosphate injection on shortage due to manufacturing delay.
- Fresenius Kabi states the reason for the shortage was increased demand. They are no longer importing Glycophos.
- Pfizer had sodium phosphate injection on shortage due to manufacturing delay

Estimated Resupply Dates

- American Regent has sodium phosphate 3 mmol/mL 5 mL, 15 mL, and 50 mL vials on back order and the company cannot estimate a release date.
- Fresenius Kabi has sodium phosphate 3 mmol/mL 5 mL vials on back order and the company estimates a release date of mid-June 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=770>

Sincalide Injection

May 8, 2017

Reason for the Shortage

- Bracco Diagnostics has Kinevac injection on shortage due to a supply disruption.
- There are no approved alternatives to Kinevac for the labeled indications.

Estimated Resupply Dates

- Bracco has Kinevac on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1032>

Norepinephrine Bitartrate Injection

May 8, 2017

Reason for the Shortage

- Claris has norepinephrine injection available.
- Pfizer has Levophed on shortage due to manufacturing delays.
- Teva has norepinephrine injection on shortage due to increased demand.

Estimated Resupply Dates

- Pfizer has Levophed 1 mg/mL 4 mL vials and 4 mL ampules on allocation.
- Teva has norepinephrine 1 mg/mL 4 mL vials on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1262>

Metronidazole Hydrochloride Injection

May 8, 2017

Reason for the Shortage

- Pfizer has metronidazole injection on shortage due to manufacturing delay.
- Baxter, BBraun, and Claris did not provide a reason for the metronidazole injection shortage.

Estimated Resupply Dates

- Baxter has metronidazole injection available in limited quantities.
- BBraun has metronidazole injection on back order and the company estimates a release date in May 2017.
- Claris has metronidazole injection on back order and the company cannot estimate a release date.
- Pfizer has metronidazole injection on back order and the company estimates a release date in late-May 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1272>

Lorazepam Injection

May 8, 2017

Reason for the Shortage

- Bedford discontinued lorazepam injection in May, 2011.
- West-Ward has product on shortage due to manufacturing delays.
- Pfizer has product on shortage due to increased demand and manufacturing delays.
- Akorn has not provided a reason for the shortage.
- Amphastar has product available.

Estimated Resupply Dates

- Akorn has lorazepam 2 mg/mL 1 mL vials on intermittent back order and is releasing product as it becomes available.
- Pfizer has lorazepam 2 mg/mL 1 mL Carpuject syringes on allocation. The 2 mg/mL 1 mL vials and 4 mg/mL 1 mL vials are on back order and the company estimates a release date of 3rd quarter 2017.
- West-Ward has lorazepam 2 mg/mL 1 mL vials on a weekly allocation. The 4 mg/mL 1 mL vials are on back order and the company estimates a release date of May 2017.
- West-Ward has Ativan 2 mg/mL 1 mL vials on back order and the company estimates a release date of May 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1270>

Disopyramide Phosphate Controlled-release Capsules

May 8, 2017

Reason for the Shortage

- Pfizer has disopyramide controlled-release capsules on shortage due to manufacturing delays.

Estimated Resupply Dates

- Pfizer has Norpace CR 100 mg capsules in 100 count and 150 mg capsules in 100 count available but with an expiration date of June 2017. The 100 mg capsules in 500 count and 150 mg capsules in 500 count are on back order and the company estimates a release date of March 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1139>

Ceftriaxone Sodium Injection

May 8, 2017

Reason for the Shortage

- Fresenius Kabi states the reason for the shortage is increased demand.
- Pfizer states the reason for the shortage is manufacturing delay.
- Sagent states the reason for the shortage is manufacturing delay.
- Sandoz cannot provide a reason for the shortage.
- West-Ward states the reason for the shortage is manufacturing delay.
- WG Critical Care states the reason for the shortage is increased demand.

Estimated Resupply Dates

- Apotex has ceftriaxone 2 gram vials on back order and the company estimates a release date of late-June 2017.
- Fresenius Kabi has ceftriaxone 2 gram vials on back order and the company estimates a released date of 2nd quarter 2017. The 500 mg vials are on back order and the company cannot estimate a release date.
- Lupin has all ceftriaxone presentations on allocation.
- Pfizer has ceftriaxone 1 gram, 1 gram ADD-Vantage, 2 gram, 10 gram, and 250 mg on allocation. The 500 mg and 2 gram ADD-Vantage vials are on back order and the company estimates a release date in mid-May 2017 for the 500 mg vials and July 2017 for the 2 gram ADD-Vantage vials.
- Sagent has ceftriaxone 1 gram vials on allocation.
- Sandoz has ceftriaxone 2 gram and 500 mg vials on back order and the company estimates a release date of late-May2017.

- West-Ward has ceftriaxone 250 mg vials on back order and the company cannot estimate a release date. The 1 gram vials are on allocation.
- WG Critical Care has ceftriaxone 10 gram vials on back order and the company estimates a release date of early-May 2017.
- Wockhardt has ceftriaxone 250 mg, 500 mg, 1 gram, and 2 gram vials on back order and the company estimates a release date of late-May to early-June 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1101>

Bumetanide Injection

May 8, 2017

Reason for the Shortage

- Pfizer has bumetanide injection on shortage due to manufacturing delays.
- West-Ward did not provide a reason for the shortage.

Estimated Resupply Dates

- Pfizer has bumetanide 0.25 mg/mL 4 mL vials on back order and the company estimates a release date of mid-June 2017.
- West-Ward has bumetanide 0.25 mg/mL 4 mL vials on a weekly allocation. The 10 mL vials are on back order and the company estimates a release date of May 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=674>

5% Lidocaine and 7.5% Dextrose Injection

May 8, 2017

Reason for the Shortage

- Pfizer has 5% lidocaine and 7.5% dextrose 2 mL ampules on shortage due to manufacturing delays.
- Pfizer is the sole supplier of this combination.

Estimated Resupply Dates

- Pfizer has 5% lidocaine and 7.5% dextrose 2 mL ampules on long-term back order and the company estimates a release date of 2nd quarter 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1245>

Promethazine Injection

May 9, 2017

Reason for the Shortage

- Teva is not marketing promethazine injection at this time.
- West-Ward states the shortage is due to manufacturing delays.
- Hospira discontinued promethazine in 2016.
- X-Gen has promethazine available.

Estimated Resupply Dates

- West-Ward has promethazine 25 mg/mL 1 mL ampules and 1 mL vials on a weekly allocation. The 50 mg/mL 1 mL ampules are on a weekly allocation. The 50 mg/mL 1 mL vials on back order and the company estimates a release date of June or July 2017.
- West-Ward has Phenergan 25 mg/mL 1 mL vials on back order and the company estimates a release date of mid-May 2017. Phenergan 25 mg/mL 1 mL ampules are on a weekly allocation. The 50 mg/mL 1 mL vials are on back order and the company estimates a release date of June or July 2017.
- X-Gen has promethazine 25 mg/mL 1 mL ampules on back order and the company estimates a release date of late-May 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=654>

Potassium Chloride Injection

May 9, 2017

Reason for the Shortage

- Baxter did not provide a reason for the current shortage.
- Pfizer has potassium chloride injection on shortage due to increase demand and manufacturing delays.

Estimated Resupply Dates

- Baxter has potassium chloride 10 mEq/50 mL and 20 mEq/50 mL vials on back order and company cannot estimate a release date. They have potassium chloride 20 mEq/500 mL in 5% dextrose and 0.2% sodium chloride, potassium chloride 20 mEq/500 mL in 5% dextrose and 0.45% sodium chloride, potassium chloride 20 mEq/1000 mL in 5% dextrose and lactated ringers, potassium chloride 20 mEq/1000 mL in 5% dextrose, potassium chloride 20 mEq/1000 mL in 5% dextrose and 0.2% sodium chloride, potassium chloride 20 mEq/1000 mL in 5% dextrose and 0.9% sodium chloride, potassium chloride 20 mEq/1000 mL in 0.9% sodium chloride, potassium chloride 30 mEq/1000 mL in 5% dextrose and 0.45% sodium chloride, potassium chloride 40 mEq/1000 mL in 0.9% sodium chloride, and potassium chloride 40 mEq/1000 mL in 5% dextrose and 0.9% sodium chloride on back order and the company cannot estimate a release date.
- Pfizer has potassium chloride 20 mEq/1000 mL in 0.9% sodium chloride on back order and the company estimates a release date of early-May 2017. Potassium chloride 2 mEq/10 mL vials are on backorder and the company estimates a release date of 3rd quarter 2017. Pfizer has potassium chloride 2 mEq/mL 250 mL vials and 10 mEq/500 mL in 5% dextrose and 0.225% sodium chloride on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=696>

Haloperidol Decanoate Injection

May 9, 2017

Reason for the Shortage

- Teva is not actively marketing haloperidol decanoate.
- West-Ward is not actively marketing haloperidol decanoate injection.
- Fresenius Kabi had haloperidol decanoate on shortage due to short-term manufacturing delays.
- Mylan discontinued haloperidol decanoate 5 mL multi-dose vials. The company did not provide a reason for the discontinuation.

Estimated Resupply Dates

- All presentation are readily available.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=526>

Gentamicin injection

May 9, 2017

Reason for the Shortage

- Pfizer has discontinued all premixed bags.
- Baxter did not provide a reason for the shortage.

Estimated Resupply Dates

- Baxter has gentamicin 60 mg/50 mL and 80 mg/50 mL premixed bags available in limited quantities.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=728>

Famotidine Injection

May 9, 2017

Reason for the Shortage

- Ben Venue stopped production in its plant in Bedford, Ohio and closed in July 2014.
- West-Ward stated the shortage was due to manufacturing delays.
- Oral famotidine products are not affected by this shortage.
- Pfizer launched famotidine injections in March 2012.
- Mylan Institutional acquired famotidine injections from Pfizer on December 6, 2013
- Baxter has famotidine premixed bags available.
- Fresenius Kabi has famotidine vials available.

Estimated Resupply Dates

- Mylan Institutional has famotidine 10 mg/mL 4 mL and 20 mL vials on back order. The company estimates a release date of late-June 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=810>

Calcium Gluconate Injection

May 9, 2017

Reason for the Shortage

- American Regent has calcium gluconate on shortage due to manufacturing delays.
- Fresenius Kabi has calcium gluconate available with alternating short-dating due to manufacturing process of the vials.
- American Regent has issued a statement that all lots of calcium gluconate may contain glass particles and filters must be used. Do not use if there are visible glass particles and filter all other product.

Estimated Resupply Dates

- American Regent has calcium gluconate 100 mg/mL 50 mL and 100 mL vials on back order and the company cannot estimate a release date.
- Fresenius Kabi has calcium gluconate 100 mg/mL 10 mL, 50 mL, and 100 mL vials on intermittent back order with regular releases.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=48>

Fentanyl Citrate Injection

May 10, 2017

Reason for the Shortage

- Akorn has fentanyl injection on shortage due to increased demand.
- West-Ward has fentanyl injection on shortage due to supply and demand issues.
- Pfizer has fentanyl injection on shortage due to manufacturing delays.

Estimated Resupply Dates

- Akorn has fentanyl 2 mL ampules and 5 mL ampules in 25 count on back order and the company cannot estimate a release date. Fentanyl 5 mL ampules in 10 count are on back order and the company estimates a release date in mid-May 2017.
- Pfizer has fentanyl 5 mL vials on back order and the company estimates a release date in mid-May 2017. The 50 mL vials are on back order and the company estimates a release date in late-June 2017.
- West-Ward has fentanyl 2 mL vials, 20 mL vials, and 50 mL vials on allocation. Fentanyl 2 mL ampules, 5 mL ampules, 20 mL ampules, and 5 mL vials are on back order and the company estimates a release date in 3rd quarter 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1273>

Etomidate Injection

May 10, 2017

Reason for the Shortage

- Ben Venue stopped production in its plant in Bedford, Ohio and closed in July 2014.
- Pfizer has Amidate on shortage due to manufacturing delays. Pfizer discontinued etomidate ampules in October 2016.
- Mylan has etomidate available.
- Par Sterile Products discontinued etomidate in early 2015.
- Sagent is no longer marketing etomidate.
- Zydus has etomidate on shortage due to an increase in demand.
- AuroMedics launched etomidate in mid-2017 and product is available.

Estimated Resupply Dates

- Pfizer has Amidate 20 mL LifeShield syringes on back order and the company cannot estimate a release date.
- Zydus has etomidate 2 mg/mL 10 mL and 20 mL vials on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=419>

Dobutamine Injection

May 10, 2017

Reason for the Shortage

- Baxter did not provide a reason for the shortage.
- Pfizer has dobutamine on shortage due to manufacturing delays.

Estimated Resupply Dates

- Baxter has dobutamine 1 mg/mL 250 mL bags on back order and the company cannot estimate a release date.
- Pfizer has dobutamine 12.5 mg/mL 20 mL and 40 mL latex-free vials on back order with an estimated release date of 2018.
- Pfizer has dobutamine 1 mg/mL, 2 mg/mL, and 4 mg/mL in 250 mL bags on intermittent back order and the company is releasing product as it becomes available.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=929>

Sodium Acetate Injection

May 11, 2017

Reason for the Shortage

- American Regent has had sodium acetate on long-term back order for several years.
- Fresenius Kabi has sodium acetate on shortage due to increased demand.
- Pfizer has sodium acetate on shortage due to manufacturing delays.

Estimated Resupply Dates

- Fresenius Kabi has sodium acetate 4 meq/mL 100 mL vials on back order and the company estimates a release date of mid- to late-June 2017.
- Pfizer has sodium acetate 2 meq/mL 20 mL vials available in limited supply. The 2 meq/mL 50 mL and 100 mL vials are on back order and the company estimates a release date of July 2017 for the 50 mL vials and early-June 2017 for the 100 mL vials.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=762>

Potassium Phosphate Injection

May 11, 2017

Reason for the Shortage

- American Regent has not had potassium phosphate injection available since 2012. It is unclear if and when product will return to market.
- Fresenius Kabi has potassium phosphate injection on shortage due to increased demand.
- Pfizer has potassium phosphate injection on shortage due to manufacturing delays.

Estimated Resupply Dates

- Fresenius Kabi has potassium phosphate 3 mmol/mL 5 mL, 15 mL, and 50 mL vials on back order and the company estimates a release date of mid-to late-June 2017 for the 5 mL vials and early-June 2017 for the 15 mL and 50 mL vials.
- Pfizer has potassium phosphate 3 mmol/mL 15 mL vials on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=709>

Methotrexate Injection

May 11, 2017

Reason for the Shortage

- Accord did not provide a reason for the shortage.
- Fresenius Kabi has methotrexate injection available.
- Mylan did not provide a reason for the shortage.
- Teva has methotrexate injection on shortage due to increased demand.
- Pfizer has methotrexate injection on shortage due to increased demand.

Estimated Resupply Dates

- Accord has methotrexate 25 mg/mL 2 mL, 10 mL, and 40 mL vials on back order and the company estimates a release date of late-June 2017.
- Mylan Institutional has methotrexate injection temporarily unavailable and the company cannot estimate a release date.
- Pfizer has methotrexate 25 mg/mL 2 mL vials and 40 mL vials on back order and the company estimates a release date of late-May 2017.
- Teva has methotrexate 25 mg/mL 2 mL, 10 mL, and 40 mL vials on allocation. Please check wholesaler for inventory.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=26>

Magnesium Sulfate Injection

May 11, 2017

Reason for the Shortage

- American Regent has had magnesium sulfate unavailable since late 2012.
- Fresenius Kabi has magnesium sulfate injection on shortage due to increased demand for the product.
- Pfizer has magnesium sulfate injection on shortage due to manufacturing delays.
- X-Gen has magnesium sulfate injection available.

Estimated Resupply Dates

- Fresenius Kabi has magnesium sulfate 500 mg/mL 50 mL vials on back order and the company estimates a release date of mid-May 2017.
- Pfizer has magnesium sulfate 500 mg/mL 10 mL syringes and 20 mL vials on back order and the company estimates a release date of 3rd quarter 2017 for the 10 mL syringes and 1st quarter 2018 for the 20 mL vials.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=757>

Diltiazem Hydrochloride Injection

May 11, 2017

Reason for the Shortage

- Akorn states the reason for the shortage is increased demand due to market conditions.
- Pfizer states the reasons for the shortage is manufacturing delays and increases in demand.
- West-Ward has diltiazem injection on shortage due to manufacturing delays caused by increased demand due to current market conditions.

Estimated Resupply Dates

- Pfizer has 100 mg ADD-Vantage vials on allocation. The 5 mg/mL 5 mL and 10 mL vials are on back order and the company estimates a release date of 3rd quarter 2017.
- West-Ward has diltiazem 5 mg/mL 25 mL vials on a weekly allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1271>

Clindamycin Injection

May 11, 2017

Reason for the Shortage

- Akorn did not provide a reason for the shortage.
- Alvogen has clindamycin injection available.
- Fresenius Kabi did not provide a reason for the shortage.
- Pfizer has Cleocin available.
- Sagent has clindamycin injection available.
- Sandoz has clindamycin injection available.

Estimated Resupply Dates

- Fresenius Kabi has clindamycin 150 mg/mL 2 mL vials available with short expiration dating of <2 months. The 6 mL vials and 60 mL bulk vials are on back order and the company cannot estimate a release date.
- Sagent has clindamycin 150 mg/mL 2 mL vials available with an expiration date of October 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1029>

Calcium Chloride Injection

May 11, 2017

Reason for the Shortage

- American Regent has calcium chloride on shortage due to manufacturing delays.
- Amphastar has calcium chloride on shortage due to increased demand.
- Pfizer has calcium chloride on shortage due to manufacturing delays.
- Mylan Institutional has withdrawn calcium chloride syringes from the market. The company recalled the syringes in April 2015 due to incompatibility of the syringes and some needless adaptors.

Estimated Resupply Dates

- American Regent has calcium chloride 100 mg/mL 10 mL vials on back order and the company cannot estimate a release date.
- Amphastar has calcium chloride 100 mg/mL 10 mL syringes on intermittent back order with regular releases.
- Pfizer has calcium chloride 100 mg/mL 10 mL Ansyr syringes on allocation. The 100 mg/mL 10 mL LifeShield syringes are on back order and the company estimates a release date of late-June 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=941>

Bupivacaine with epinephrine Injection

May 11, 2017

Reason for the Shortage

- Fresenius Kabi has bupivacaine and epinephrine on shortage due to increased demand and manufacturing delays.
- Pfizer has bupivacaine with epinephrine on shortage due to manufacturing delays.

Estimated Resupply Dates

- Fresenius Kabi has 0.25% Sensorcaine-MPF with epinephrine 10 mL and 30 mL vials on back order and the company estimates a release date of mid-May 2017. The 0.25% Sensorcaine with epinephrine 50 mL vials are on back order and the company estimates a release date of mid-May 2017. The 0.5% Sensorcaine-MPF with epinephrine 10 mL vials are on back order and the company estimates a release date of mid-May 2017. The 0.5% Sensorcaine-MPF with epinephrine 30 mL vials are on back order and the company estimates a release date of mid-May 2017. The 0.5% Sensorcaine-MPF with epinephrine 30 mL vials sterile packs are on back order and the company estimates a release date of mid-May 2017. The 0.5% Sensorcaine with epinephrine 50 mL vials are on back order and the company estimates a release date of mid-May 2017.
- Pfizer has 0.25% bupivacaine with epinephrine 30 mL preservative-free vials and 50 mL vials on allocation. The 0.5% bupivacaine with epinephrine 30 mL preservative-free vials are on back order and the company estimates a release date of mid-June 2017. The 0.5% bupivacaine with epinephrine 10 mL preservative-free vials are on allocation. The 0.5% bupivacaine with epinephrine 50 mL vials are on back order and the company estimates a release date of mid-June 2017.
- Pfizer has 0.25% Marcaine with epinephrine 50 mL vials on allocation. The 0.25% Marcaine with epinephrine 10 mL preservative-free vials are on allocation. The 0.5% Marcaine with epinephrine 10 mL preservative-free vials are on back order and the company estimates a release date of June 2017. The 0.5% Marcaine with epinephrine 30 mL preservative-free vials are on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=937>

Ampicillin Sulbactam

May 11, 2017

Reason for the Shortage

- Mylan Institutional discontinued ampicillin sulbactam 1.5 gram and 3 gram vials.
- Pfizer has discontinued generic ampicillin sulbactam.
- Sandoz cannot provide a reason for the shortage.
- Sagent has ampicillin sulbactam vials on allocation due to manufacturing delays.
- WG Critical Care states the shortage was due to increased demand.

Estimated Resupply Dates

- AuroMedics has ampicillin sulbactam 1.5 gram, 3 gram, and 15 gram vials on intermittent back order and the company is releasing product as it becomes available.
- Fresenius Kabi has ampicillin sulbactam 1.5 gram, 3 gram, and 15 gram vials on back order and the company cannot estimate a release date.
- Mylan Institutional has ampicillin sulbactam 15 gram bulk vials on back order and the company estimates a release date of early-June 2017.
- Sagent has ampicillin sulbactam 3 gram and 15 gram vials on allocation.
- Sandoz has ampicillin sulbactam 1.5 gram, 3 gram, and 15 gram vials temporarily unavailable and the company cannot estimate a release date.
- West-Ward has ampicillin sulbactam 1.5 gram, 3 gram, and 15 gram vials on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=805>

Trace Elements Injection

May 15, 2017

Reason for the Shortage

- American Regent did not provide a reason for the shortage.

Estimated Resupply Dates

- American Regent has Multitrac-4 Concentrate 1 mL vials, Multitrac-5 10 mL vials, Multitrac-5 Concentrate 1 mL and 10 mL vials in limited supply. The Multitrac-4 10 mL vials, Multitrac-4 Concentrate 10 mL vials, and trace elements-4 pediatric vials are on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=785>

Selenium Injection

May 15, 2017

Reason for the Shortage

- American Regent did not provide a reason for the shortage.

Estimated Resupply Dates

- American Regent has selenium 40 mcg/mL 10 mL vials available.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=784>

Lidocaine with Epinephrine Injection

May 15, 2017

Reason for the Shortage

- Fresenius Kabi has Xylocaine with epinephrine presentations on shortage due to increased demand for the product and manufacturing delays.
- Pfizer has lidocaine with epinephrine presentations on shortage due to manufacturing delays.

Estimated Resupply Dates

- Pfizer has 1% lidocaine with epinephrine (1:100,000) 20 mL and 30 mL vials on back order and the company estimates a release date of early-June 2017. The 1% lidocaine with epinephrine (1:100,000) 50 mL vials are on back order and the company estimates a release date of mid-June 2017. The 0.5% lidocaine with epinephrine (1:200,000) 50 mL vials are on back order and the company estimates a release date of October 2017. The 1.5% lidocaine with epinephrine (1:200,000) 30 mL vials are on back order and the company estimates a release date of September 2017. The 2% lidocaine with epinephrine (1:200,000) 20 mL vials are on back order and the company estimates a release date of mid-June 2017. The 2% lidocaine with epinephrine (1:100,000) 20 mL vials are on back order and the company estimates a release date of late-July 2017. The 2% lidocaine with epinephrine (1:100,000) 30 mL vials are on back order and the company estimates a release date of early-August 2017. The 2% lidocaine with epinephrine (1:100,000) 50 mL vials are on back order and the company estimates a release date of late-July 2017.
- Fresenius Kabi has 1% Xylocaine with epinephrine (1:200,000) 10 mL, 20 mL, and 50 mL vials back order and the company estimates a release date of late-May 2017 for the 10 mL vials and mid-May 2017 for the 20 mL and 50 mL vials. The 1% Xylocaine-MPF with epinephrine (1:200,000) 10 mL and 30 mL vials are on back order and the company estimates a release date of late-May 2017 for the 10 mL vials and mid-May 2017 for the 30 mL vials. The 1% Xylocaine-MPF with epinephrine (1:200,000) 30 mL vials in sterile packs are on back order and the company estimates a release date of mid-June 2017. The 1.5% Xylocaine-MPF with epinephrine (1:200,000) 10 mL vials are on back order and the company estimates a release date of late-May 2017. The 2% Xylocaine with epinephrine (1:200,000) 20 mL vials are on back order and the

company estimates a release date of mid-May 2017. The 2% Xylocaine-MPF with epinephrine (1:200,000) 10 mL vials are on back order and the company estimates a release date of late-May 2017. The 2% Xylocaine-MPF with epinephrine (1:200,000) 20 mL vials in sterile packs are on back order and the company estimates a release date of mid-May 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=860>

Hepatitis A Virus Vaccine Inactivated

May 15, 2017

Reason for the Shortage

- Merck did not provide a reason for the Vaqta shortage.
- GlaxoSmithKline has Havrix available.

Estimated Resupply Dates

- Merck has Vaqta pediatric/adolescent formulation 25 U/0.5 mL prefilled syringes in 10 count on back order and the company estimates a release date of 3rd quarter 2017.
- Merck has Vaqta adult formulation 50 U/1 mL vials in 1 count on back order and the company estimates product will not be available in 2017. Vaqta 50 U/1 mL vials in 10 count are on back order and the company estimates a release date of 2nd quarter 2017. Vaqta 50 U/1 mL prefilled syringes are on back order and the company estimates a release date of 4th quarter 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=180>

Cefotaxime Injection

May 15, 2017

Reason for the Shortage

- Hospira has discontinued Claforan. Sanofi-Aventis manufactured Claforan for Hospira and is no longer making the product.
- Baxter discontinued Claforan in late-2015.
- West-Ward has cefotaxime on shortage due to increased demand.

Estimated Resupply Dates

- West-Ward has cefotaxime 500 mg, 1 gram, 2 gram, and 10 gram vials on long-term back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=826>

Caffeine and Sodium Benzoate Injection

May 15, 2017

Reason for the Shortage

- American Regent did not provide a reason for the shortage.

Estimated Resupply Dates

- American Regent has caffeine and sodium benzoate 2 mL vials on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=817>

Sodium Bicarbonate Injection

May 16, 2017

Reason for the Shortage

- Amphastar has sodium bicarbonate injection on shortage due to increased demand.
- Pfizer has sodium bicarbonate injection on shortage due to manufacturing delays.

Estimated Resupply Dates

- Amphastar has 8.4 % sodium bicarbonate 50 mL syringes on allocation.
- Pfizer has 8.4 % sodium bicarbonate 50 mL syringes are on back order and the company estimates a release date of early-June 2017. The 8.4 % sodium bicarbonate 50 mL vials are on back order and the company estimates a release date of August 2017. The 8.4% sodium bicarbonate 10 mL syringes and 7.5% sodium bicarbonate 50 mL syringes are on back order and the company cannot estimate a release date. The 4.2% sodium bicarbonate 10 mL syringes are on back order and the company estimates a release date of early-July 2017.
- Pfizer has Neut additive solution in 5 mL vials on back order and the company estimates a release date of 3rd quarter 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=788>

Rocuronium Injection

May 16, 2017

Reason for the Shortage

- Fresenius Kabi has rocuronium on shortage due to delay of raw materials.
- Pfizer has rocuronium on shortage due to manufacturing delays.
- Sagent has rocuronium on shortage due to increased demand.
- X-Gen has rocuronium on shortage due to increased demand.
- AuroMedics will be launching rocuronium with an estimated launch date of June 2017.

Estimated Resupply Dates

- Fresenius Kabi has rocuronium 10 mg/mL 5 mL and 10 mL vials on back order and the company estimates a release date of 3rd quarter 2017.
- Pfizer has rocuronium 10 mg/mL 5 mL and 10 mL vials on back order and the company estimates a release date of late-July 2017.
- Sagent has rocuronium 10 mg/mL 5 mL and 10 mL vials on back order and the company estimates a release date of May 2017 for the 5 mL vials and cannot estimate a release date for the 10 mL vials.
- Sandoz has rocuronium 10 mg/mL 5 mL and 10 mL vials on allocation.
- X-Gen has rocuronium 10 mg/mL 5 mL vials on back order and the company estimates a release date of late-May 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=434>